Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Compl	ete if Known	
Application Number	10/701,265	
Filing Date	11-04-2003	
First Named Inventor	Brenda F. Baker	
Art Unit	1635	
Examiner Name	Jennifer S. Pitrak	
Attorney Docket Number	ISIS-5300	

		U. S. I	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	2002/0049173 A1	04-25-2002	Bennett et al.	
	2	2002/0071826 A1	06-13-2002	Tamarkin et al.	
	3	2002/0081577 A1	06-27-2002	Kilkuskie et al.	
	4	2002/0081736 A1	06-27-2002	Conroy et al.	
	5	2002/0102267 A1	08-01-2002	Lu et al.	
	6	2002/0147332 A1	10-10-2002	Kaneko	
	7	2002/0156235 A1	10-24-2002	Manoharan et al.	
	8	2002/0162126 A1	10-30-2002	Beach et al.	
	9	2002/0165189 A1	11-07-2002	Crooke	
	10	2002/1051512 A1	10-17-2002	Peyman et al.	
	11	2003/0004325 A1	01-02-2003	Cook et al.	
	12	2003/0027780 A1	02-06-2003	Hardee et al.	
	13	2003/0096286 A1	05-22-2003	Crooke	
	14	2003/0096287 A1	05-22-2003	Crooke	
	15	2003/0096784 A1	05-22-2003	Crooke	
	16	2003/0119777 A1	06-26-2003	Crooke	
	17	2003/0158403 A1	08-21-2003	Manoharan et al.	
	18	2003/0166282 A1	09-04-2003	Brown et al.	
	19	2003/0175906 A1	09-18-2003	Manoharan et al.	Ï
	20	2003/0187240 A1	10-02-2003	Cook et al.	
	21	2003/0190635 A1	10-09-2003	McSwiggen	
	22	2003/0207804 A1	11-06-2003	Manoharan et al.	
	23	2003/0224377 A1	12-04-2003	Wengel et al.	
	24	2004/0001811 A1	01-01-2004	Kreutzer et al.	
	25	2004/0009938 A1	01-15-2004	Manoharan et al.	
	26	2004/0014957 A1	01-22-2004	Eldrup et al.	

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known			
Application Number	10/701,265		
Filing Date	11-04-2003		
First Named Inventor	Brenda F. Baker		
Art Unit	1635		
Examiner Name	Jennifer S. Pitrak		
Attorney Docket Number	ISIS-5300		

U. S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	27	2004/0102618 A1	05-27-2004	Crooke et al.	
	28	2004/0171033 A1	09-02-2004	Baker et al.	
	29	2004/0259247 A1	12-23-2004	Tuschl et al.	
	30	2005/0020525 A1	01-27-2005	McSwiggen et al.	
	31	2005/0080246 A1	04-14-2005	Allerson et al.	
	32	2005/0164209 A1	07-28-2005	Bennett et al.	
	33	2005/0181382 A1	08-18-2005	Zamore et al.	
	34	2005/0221275 A1	10-06-2005	Bennett et al.	
	35	2005/0245474 A1	11-03-2005	Baker et al.	
	36	2005/0273868 A1	12-08-2005	Rana	
	37	2006/0127891 A1	06-15-2006	McSwiggen et al.	
	38	2007/0032446 A1	02-08-2007	Cook et al.	
	39	4,381,344	04-26-1983	Rideout et al.	
	40	4,415,732	11-15-1983	Caruthers et al.	
	41	4,426,330	01-17-1984	Sears	
	42	4,458,066	07-03-1984	Caruthers et al.	
	43	4,476,301	10-09-1954	Imbach et al.	
	44	4,500,707	02-19-1985	Caruthers et al.	
	45	4,511,713	04-16-1985	Miller et al.	
	46	4,534,899	08-13-1985	Sears	
	47	4,587,044	05-06-1986	Miller	
	48	4,605,735	08-12-1986	Miyoshi	
	49	4,667,025	05-19-1987	Miyoshi	
	50	4,668,777	05-26-1987	Caruthers et al.	
	51	4,689,320	08-25-1987	Kaji	
	52	4,725,677	02-16-1988	Koster et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	4

Compl	ete if Known	
Application Number	10/701,265	
Filing Date	11-04-2003	
First Named Inventor	Brenda F. Baker	
Art Unit	1635	
Examiner Name Jennifer S. Pitrak		
Attorney Docket Number	ISIS-5300	

U. S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	53	4,760,017	07-26-1988	McCormick	
	54	4,762,779	08-09-1988	Snitman	
	55	4,789,737	12-06-1988	Miyoshi	
	56	4,824,941	04-25-1989	Gordon	
	57	4,828,979	05-09-1989	Klevan	
	58	4,835,263	05-30-1989	Nguyen	
	59	4,845,205	07-04-1989	Huynh Dinh et al.	
	60	4,849,320	07-18-1989	Irving et al.	
	61	4,849,513	07-18-1989	Smith et al.	
	62	4,876,335	10-24-1989	Yamane	
	63	4,904,582	02-27-1990	Tullis	
	64	4,924,624	05-15-1990	Suhadolnik et al.	
	65	4,948,882	08-14-1990	Ruth	
	66	4,958,013	09-18-1990	Letsinger	
	67	4,965,350	10-23-1990	Inoue et al.	
	68	4,973,679	11-27-1990	Caruthers et al.	
	69	4,981,957	01-01-1991	Lebleu	
	70	5,000,000	03-19-1991	Ingram et al.	
	71	5,013,556	05-07-1991	Woodle et al.	
	72	5,082,830	01-21-1992	Brakel	
	73	5,108,921	04-28-1992	Low et al.	
	74	5,109,124	04-28-1992	Ramathandran	
	75	5,112,963	05-12-1992	Pieles	
	76	5,118,800	06-02-1992	Fung	
	77	5,118,802	06-02-1992	Smith	
	78	5,132,418	07-21-1992	Caruthers et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	44

Compl	Complete if Known			
Application Number	10/701,265			
Filing Date	11-04-2003			
First Named Inventor	Brenda F. Baker			
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

U. S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	79	5,134,066	07-28-1992	Rogers et al.	
	80	5,138,045	08-11-1992	Cook	
	81	5,149,782 A	09-22-1992	Chang et al.	
	82	5,166,315	11-24-1992	Summerton et al.	
	83	5,175,273	12-29-1992	Bischofberger et al.	
	84	5,177,196	01-05-1993	Meyer, Jr. et al.	
	85	5,185,444	02-09-1993	Summerton et al.	
	86	5,188,897	02-23-1993	Suhadolnik et al.	
	87	5,194,599	03-16-1993	Froehler et al.	
	88	5,212,295 A	05-18-1993	Cook	
	89	5,213,804	05-25-1993	Martin et al.	
	90	5,214,134	05-25-1993	Weis et al.	
	91	5,214,135 A	05-25-1993	Srivastava et al.	
	92	5,214,136	05-25-1993	Lin	
	93	5,216,141	06-01-1993	Benner	
	94	5,218,105	06-08-1993	Cook	
	95	5,227,170	07-13-1993	Sullivan	
	96	5,245,022	09-14-1993	Weis	
	97	5,254,469	10-19-1993	Warren	ĺ
	98	5,258,506	11-02-1993	Urdea	
	99	5,262,536	11-16-1993	Hobbs	
	100	5,264,221	11-23-1993	Tagawa et al.	
	101	5,264,423	11-23-1993	Cohen et al	
	102	5,272,250	12-21-1993	Spielvogel	
	103	5,276,019	01-04-1994	Cohen et al	
	104	5,278,302	01-11-1994	Caruthers et al.	

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

Complete if Known

		U. S. I	PATENT DOC	UMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	105	5,286,717	02-15-1994	Cohen et al	
	106	5,292,873	03-08-1994	Rokita	
	107	5,317,098	05-31-1994	Shizuya	
	108	5,319,080	06-07-1994	Leumann	
	109	5,321,131	06-14-1994	Agrawal et al.	
	110	5,354,844	10-11-1994	Beug et al.	
	111	5,356,633	10-18-1994	Woodle et al.	
	112	5,367,066	11-22-1994	Urdea et al.	
	113	5,371,241	12-06-1994	Brush	
	114	5,391,723	02-21-1995	Priest	
	115	5,393,878	02-28-1995	Leumann	
	116	5,395,619	03-07-1995	Zalipsky et al.	
	117	5,399,676	03-21-1995	Froehler et al.	
	118	5,405,938	04-11-1995	Summerton et al.	
	119	5,405,939	04-11-1995	Suhadolnik et al.	
	120	5,414,077	05-09-1995	Lin	
	121	5,416,016	05-16-1995	Low et al.	
	122	5,416,203	05-16-1995	Letsinger	
	123	5,417,978	05-23-1995	Tari et al.	
	124	5,432,272	07-11-1995	Benner	
	125	5,434,257	07-18-1995	Matteucci et al.	
	126	5,446,137	08-29-1995	Maag	
	127	5,451,463	09-19-1995	Nelson	
	128	5,453,496	09-26-1995	Caruthers et al.	
	129	5,455,233	10-03-1995	Spielvogel et al.	
	130	5,457,187	10-10-1995	Gmeiner et al.	

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Compi	ete If Known	
Application Number	10/701,265	
Filing Date	11-04-2003	
First Named Inventor	Brenda F. Baker	
Art Unit	1635	
Examiner Name	Jennifer S. Pitrak	
Attorney Docket Number	ISIS-5300	

		U. S.	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	131	5,459,127	10-17-1995	Felgner et al.	
	132	5,462,854	10-31-1995	Coassin et al.	
	133	5,466,677	11-14-1995	Baxter et al.	
	134	5,469,854	11-28-1995	Unger et al.	
	135	5,470,967	11-28-1995	Huie et al.	
	136	5,486,603	01-23-1996	Bahr	
	137	5,502,177	03-26-1996	Matteucci et al.	
	138	5,510,475	04-23-1996	Agrawal	
	139	5,512,295	04-30-1996	Kornberg et al.	
	140	5,512,439	04-30-1996	Hornes	
	141	5,512,667	04-30-1996	Reed	
	142	5,514,785	05-07-1996	Van Ness	
	143	5,519,126	05-21-1996	Hecht	
	144	5,521,291	05-28-1996	Curiel et al.	
	145	5,525,465	06-11-1996	Haralambidis	
	146	5,525,711	06-11-1996	Hawkins et al.	
	147	5,527,528	06-18-1996	Allen et al.	
	148	5,527,899	06-18-1996	Froehler	
	149	5,532,130	07-02-1996	Alul	Ï
	150	5,534,259	07-09-1996	Zalipsky et al.	
	151	5,536,821	07-16-1996	Agrawal et al.	
	152	5,539,082	07-23-1996	Nielsen et al.	
	153	5,541,306	07-30-1996	Agrawal et al.	
	154	5,541,307	07-30-1996	Cook et al.	
	155	5,541,313	07-30-1996	Ruth	
	156	5,543,152	08-06-1996	Webb et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 44

Compl	ete if Known
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

U. S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	157	5,543,158	08-06-1996	Gref et al.	
	158	5,545,730	08-13-1996	Urdea	
	159	5,547,932	08-20-1996	Curiel et al.	
	160	5,550,111	08-27-1996	Suhadolnik et al.	
	161	5,552,538	09-13-1996	Urdea	
	162	5,552,540	09-03-1996	Haralambidis	
	163	5,556,948	09-17-1996	Tagawa et al.	
	164	5,561,225	10-01-1996	Maddry et al.	
	165	5,563,253	10-08-1996	Agrawal et al.	
	166	5,565,552	10-15-1996	Magda	
	167	5,565,555	10-15-1996	Froehler et al.	
	168	5,567,810	10-22-1996	Weis	
	169	5,571,799	11-05-1996	Tkachuk et al.	
	170	5,574,142	11-12-1996	Meyer	
	171	5,576,302 A	11-19-1996	Cook et al.	
	172	5,578,717	11-26-1996	Urdea	
	173	5,578,718	11-26-1996	Cook	
	174	5,580,575	12-03-1996	Unger et al.	
	175	5,580,731	12-03-1996	Chang	
	176	5,582,188 A	12-10-1996	Benderev et al.	
	177	5,583,020	12-17-1996	Arnold, Jr. et al.	
	178	5,585,481	12-17-1996	Arnold	
	179	5,587,361	12-24-1996	Cook et al.	
	180	5,587,371	12-24-1996	Sessler	
	181	5,587,469	12-24-1996	Cook et al.	
	182	5,591,584	01-07-1997	Chang	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	8	of	44	Attorney Docket Nu

Compl	ete if Known
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

U. S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	183	5,591,721	01-07-1997	Agrawal et al.	
	184	5,591,722	01-07-1997	Montgomery et al.	
	185	5,594,121	01-14-1997	Froehler et al.	
	186	5,595,726	01-21-1997	Magda	
	187	5,595,756	01-21-1997	Bally et al.	
	188	5,596,086	01-21-1997	Matteucci et al.	
	189	5,596,091	01-21-1997	Switzer et al.	
	190	5,597,696	01-28-1997	Linn	
	191	5,597,909	01-28-1997	Urdea	
	192	5,599,797 A	02-04-1997	Cook et al.	
	193	5,599,923	02-04-1997	Sessler	
	194	5,599,925	02-04-1997	Torii	
	195	5,599,928	02-04-1997	Hemmi et al.	
	196	5,607,923 A	03-04-1997	Cook et al.	
	197	5,608,046	03-04-1997	Cook	
	198	5,610,289	03-11-1997	Cook et al.	
	199	5,610,300	03-11-1997	Altmann	
	200	5,612,469 A	03-18-1997	Goodchild	
	201	5,614,621	03-25-1997	Ravikumar et al.	
	202	5,618,704	04-08-1997	Sanghvi et al.	
	203	5,623,070	04-22-1997	Cook et al.	
	204	5,625,050	04-29-1997	Beaton et al.	
	205	5,627,053	05-06-1997	Usman	
	206	5,633,360	05-27-1997	Bischofberger et al.	
	207	5,634,488 A	06-03-1997	Martin, Jr.	
	208	5,635,488 A	06-03-1997	Cook et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

heet	9	of	4

Compl	ete if Known
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

U. S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	209	5,639,647 A	06-17-1997	Usman et al.	
	210	5,643,889 A	07-01-1997	Suhadolnik et al.	
	211	5,645,985	07-08-1997	Froehler et al.	
	212	5,646,265	07-08-1997	Mcgee	
	213	5,646,269	07-08-1997	Matteucci et al.	
	214	5,658,731 A	08-19-1997	Sproat et al.	
	215	5,658,873	08-19-1997	Bertsch-Frank	
	216	5,661,134 A	08-26-1997	Cook et al.	
	217	5,663,312	09-02-1997	Chaturvedula	
	218	5,663,360 A	09-02-1997	Bortolaso et al.	
	219	5,670,633	09-23-1977	Cook et al.	
	220	5,672,662 A	09-30-1997	Harris et al.	
	221	5,672,695 A	09-30-1997	Eckstein et al.	
	222	5,672,697	09-30-1997	Buhr et al.	
	223	5,677,289 A	10-14-1997	Torrence et al.	
	224	5,677,437	10-14-1997	Teng et al.	
	225	5,677,439	10-14-1997	Weis et al.	
	226	5,681,941	10-28-1997	Cook et al.	
	227	5,684,142 A	11-04-1997	Mishra et al.	
	228	5,684,143 A	11-04-1997	Gryaznov et al.	
	229	5,684,243 A	11-04-1997	Gururaja et al.	
	230	5,688,941	11-18-1997	Cook	
	231	5,698,687 A	12-16-1997	Eckstein et al.	
	232	5,700,785 A	12-23-1997	Suhadolnik et al.	
	233	5,700,920	12-23-1997	Altmann	
	234	5,714,166 A	02-03-1998	Tomalia et al.	

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

10

LOSURE PLICANT		Filing Date	11-04-2003
		First Named Inventor	Brenda F. Baker
		Art Unit	1635
		Examiner Name	Jennifer S. Pitrak
	44	Attorney Docket Number	ISIS-5300

Application Number

Complete if Known

10/701,265

		U. S.	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines Where Relevant Passages or Relevan Figures Appear
	235	5,714,331	02-03-1998	Buchardt et al.	
	236	5,716,824 A	02-10-1998	Beigelman et al.	
	237	5,719,262	02-17-1998	Buchardt et al.	
	238	5,721,218	02-24-1998	Froehler et al.	
	239	5,726,297 A	03-10-1998	Gryaznov et al.	
	240	5,750,666 A	05-12-1998	Caruthers et al.	
	241	5,750,692	05-12-1998	Cook et al.	
	242	5,763,588	06-09-1998	Matteucci et al.	
	243	5,770,713	06-23-1998	Imbach et al.	
	244	5,770,716 A	06-23-1998	Khan et al.	
	245	5,777,092 A	07-07-1998	Cook et al.	
	246	5,789,576 A	08-04-1998	Daily et al.	
	247	5,792,608	08-11-1998	Swaminathan et al.	
	248	5,792,747	08-11-1998	Schally	
	249	5,792,844 A	08-11-1998	Sanghvi et al.	
	250	5,792,847 A	08-11-1998	Buhr et al.	
	251	5,801,154 A	09-01-1998	Baracchini et al.	
	252	5,808,023 A	09-15-1998	Sanghvi et al.	
	253	5,817,781 A	10-06-1998	Swaminathan et al.	
	254	5,830,635 A	11-03-1998	Agnello	
	255	5,830,653	11-03-1998	Froehler et al.	
	256	5,837,835 A	11-17-1998	Gryaznov et al.	
	257	5,840,876 A	11-24-1998	Beigelman et al.	
	258	5,859,221 A	01-12-1999	Cook et al.	
	259	5,872,232 A	02-16-1999	Cook et al.	
	260	5,874,553	02-23-1999	Peyman et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of

Complete if Known				
Application Number	10/701,265			
Filing Date	11-04-2003			
First Named Inventor	Brenda F. Baker			
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

		U. S.	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	261	5,914,396 A	06-22-1999	Cook et al.	
	262	5,936,080 A	08-10-1999	Stec et al.	
	263	5,945,521 A	08-31-1999	Just et al.	
	264	5,965, 720 A	10-12-1999	Gryaznov et al.	
	265	5,965, 7 21 A	10-12-1999	Cook et al.	
	266	5,969,116 A	10-19-1999	Martin	
	267	5,969,118 A	10-19-1999	Sanghvi et al.	
	268	5,986,083 A	11-16-1999	Dwyer et al.	
	269	5,998,588 A	12-07-1999	Hoffman et al.	
	270	6,001,841	12-14-1999	Cook et al.	
	271	6,005,087	12-21-1999	Cook et al.	
	272	6,005,094 A	12-21-1999	Simon et al.	
	273	6,005,096	12-21-1999	Matteucci et al.	
	274	6,007,992	12-28-1999	Lin et al.	
	275	6,013, 7 85 A	01-11-2000	Bruice et al.	
	276	6,015,886 A	01-18-2000	Dale et al.	
	277	6,020,475	02-01-2000	Capaldi et al.	
	278	6,025,140	02-15-2000	Langel et al.	
	279	6,028,183	02-22-2000	Lin et al.	
	280	6,028,188 A	02-22-2000	Arnold, Jr. et al.	
	281	6,043,060	03-28-2000	Imanishi	
	282	6,043,352 A	03-28-2000	Manoharan et al.	
	283	6,051,699	04-18-2000	Ravikumar	
	284	6,087,484 A	07-11-2000	Goodchild	
	285	6,096,875 A	08-01-2000	Khan et al.	
	286	6,111,085 A	08-29-2000	Cook et al.	

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Compl	ete if Known
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

		U. S. I	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	287	6,121,437	09-19-2000	Guzaev et al.	
	288	6,127,346	10-03-2000	Peyman et al.	
	289	6,127,533 A	10-03-2000	Cook et al.	
	290	6,147,200	11-14-2000	Manoharan et al.	
	291	6,153,737 A	11-28-2000	Manoharan et al.	
	292	6,166,188 A	12-26-2000	Cook et al.	
	293	6,169,177	01-02-2001	Manoharan	
	294	6,172,208 B1	01-09-2001	Cook	
	295	6,172,209	01-09-2001	Manoharan et al.	
	296	6,172,216 B1	01-09-2001	Bennett et al.	
	297	6,207,646	03-27-2001	Krieg et al.	
	298	6,222,025 B1	04-24-2001	Cook et al.	
	299	6,227,982 B1	05-08-2001	Wurster	
	300	6,239,265 B1	05-29-2001	Cook	
	301	6,239,272 B1	05-29-2001	Beigelman et al.	
	302	6,262,241 B1	07-17-2001	Cook et al.	
	303	6,268,490	07-31-2001	Imanishi et al.	
	304	6,271,358 B1	08-07-2001	Manoharan et al.	
	305	6,277,634	08-21-2001	McCall et al.	
	306	6,277,967 B1	08-21-2001	Manoharan	
	307	6,281,201 B1	08-28-2001	Suhadolnik et al.	
	308	6,284,538 B1	09-04-2001	Monia et al.	
	309	6,287,860	09-11-2001	Monia et al.	
	310	6,300,319 B1	10-09-2001	Manoharan	
	311	6,307,040 B1	10-23-2001	Cook et al.	
	312	6,326,358 B1	12-04-2001	Manoharan	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 44

Compl	Complete if Known			
Application Number	10/701,265			
Filing Date	11-04-2003			
First Named Inventor	Brenda F. Baker			
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

		U. S.	PATENT DOC	JMENTS	
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	313	6,326,478	12-04-2001	Cheruvallath et al.	
	314	6,331,617 B1	12-18-2001	Weeks et al.	
	315	6,335,432 B1	01-01-2002	Segev	
	316	6,335,434 B1	01-01-2002	Guzaev et al.	
	317	6,335,437 B1	01-01-2002	Manoharan et al.	
	318	6,344,436 B1	02-05-2002	Smith et al.	
	319	6,358,931 B1	03-19-2002	Cook et al.	
	320	6,365,379 B1	04-02-2002	Lima et al.	
	321	6,395,437 B1	05-28-2002	Wollesen	
	322	6,395,492 B1	05-28-2002	Manoharan et al.	
	323	6,410,702 B1	06-25-2002	Swaminathan et al.	
	324	6,414,127	07-02-2002	Lin et al.	
	325	6,420,549 B1	07-16-2002	Cook et al.	
	326	6,426,220	07-30-2002	Bennett et al.	
	327	6,440,943 B1	08-27-2002	Cook et al.	
	328	6,444,806 B1	09-03-2002	Veerapanani et al.	
	329	6,465,628	10-15-2002	Ravikumar et al.	
	330	6,476,205 B1	11-05-2002	Buhr et al.	
	331	6,486,308 B2	11-26-2002	Kutyavin et al.	Ï
	332	6,525,031 B2	02-25-2003	Manoharan	
	333	6,528,631 B1	03-04-2003	Cook et al.	
	334	6,531,584 B1	03-11-2003	Cook et al.	
	335	6,534,639 B1	03-18-2003	Manoharan et al.	
	336	6,559,279 B1	05-06-2003	Manoharan et al.	
	337	6,593,466	07-15-2003	Manoharan et al.	
	338	6,656,730	12-02-2003	Manoharan	

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

Complete if Known

	U. S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document Number Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	339	6,670,461	12-30-2003	Wengel et al.			
	340	6,673,611 B2	01-06-2004	Thompson et al.			
	341	6,683,167 B2	01-27-2004	Metelev et al.			
	342	6,794,499	09-21-2004	Wengel et al.			
	343	6,887,906	05-03-2005	Teng et al.			
	344	RE34,069	09-15-1992	Koster et al.			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No	Foreign Patent Document Country Code- Number -Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	345	CA 2,017,369 C	01-23-2001	Roche Diagnostics GmbH		
	346	DE 10100588 A1	07-18-2002	Ribopharma		
	347	DE 3915432 A1	11-15-1990	Klockner-Humboldt-Deutz AG		
	348	DE 4110085 A1	01-10-1992	Boehringer Ingelheim Int'l. GmbH		
	349	EP 0260032 A2	03-16-1988	Ajinmoto Co., Inc.		
	350	EP 0269574 A2	06-01-1988	Nippon Zoki Pharmaceutical Co. Ltd.		
	351	EP 0287313 A2	10-19-1988	Marquez		
	352	EP 0339330 A2	11-02-1989	Spradau, Hans F.W.		
	353	EP 0417999 A1	03-20-1991	The Wellcome Foundation Limited		
	354	EP 1389637 A1	02-18-2004	Atugen AG		
	355	WO 00/08044 A1	02-17-2000	Isis Pharmaceuticals, Inc.		
	356	WO 00/76554 A1	12-21-2000	Isis Pharmaceuticals, Inc.		
	357	WO 01/049687 A2	07-12-2001	K.U. Leuven Research & Development		
	358	WO 02/36743 A2	05-10-2002	Isis Pharmaceuticals, Inc.		
	359	WO 02/38578 A1	05-16-2002	Chattopadhyaya		

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

15 of

Sheet

FOREIGN PATENT DOCUMENTS Cite No Foreign Patent Document Publication Date Name of Patentee or Pages, Columns, Examiner Initials Country Code- Number -Kind MM-DD-YYYY Applicant of Cited Document Lines, Where Code (if known) Relevant Passages or Relevant Figures Appear 360 WO 03/004602 A2 01-16-2003 Isis Pharmaceuticals, Inc. 361 WO 03/070918 A2 08-28-2003 Ribozyme Pharm Inc. 362 WO 2004/015107 A2 02-19-2004 Atugen AG 363 WO 2004/041889 A2 05-21-2004 Isis Pharm. Isis Pharm. 364 WO 2004/043977 A2 05-27-2004 365 WO 2004/043978 A2 05-27-2004 Isis Pharm 366 WO 2004/043979 A2 05-27-2004 Isis Pharm. Isis Pharm. 367 WO 2004/044133 A2 05-27-2004 368 WO 2004/044136 A2 05-27-2004 Isis Pharm 369 WO 2004/044138 A2 05-27-2004 Isis Pharm. 370 WO 2004/044139 A2 05-27-2004 Isis Pharmaceuticals Inc. 371 WO 2004/044140 A2 05-27-2004 Isis Pharm 372 WO 2004/083430 A2 09-30-2004 Elmen et al 373 WO 2004/097049 A1 11-11-2004 Isis Pharmaceuticals, Inc. 374 WO 2004/113496 A2 12-29-2004 Isis Pharm WO 2005/027962 A2 03-31-2005 Isis Pharm 375 376 WO 89/12060 A1 12-14-1989 Benner 377 WO 90/15814 A1 12-27-1990 Meiogenics, Inc. 378 WO 91/06556 A1 05-16-1991 Gilead Sciences, Inc. 379 WO 91/10671 A1 07-25-1991 Isis Pharmaceuticals, Inc. Europaisches WO 91/15499 A1 10-17-1991 Laboratorium Fur 380 Molekularbiologie WO 92/02258 A1 02-20-1992 Isis Pharmaceuticals. Inc. 381 382 WO 92/03452 A1 03-05-1992 Isis Pharmaceuticals, Inc. 383 WO 92/03568 A1 03-05-1992 Isis Pharmaceuticals, Inc. 384 WO 93/07883 A1 04-29-1993 Isis Pharmaceuticals. Inc.

2 h - 12 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -				Complete if Known	
Substitute for 1449/PTO				Application Number	10/701,265
	DRMATION			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
(use as many sheets as necessary)				Examiner Name	Jennifer S. Pitrak
Sheet	16	of	44	Attorney Docket Number	ISIS-5300

		FOREI	GN PATENT D	OCUMENTS		
Examiner Initials	Cite No	Foreign Patent Document Country Code-Number -Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	385	WO 93/24510 A1	12-09-1993	Centre National de la Recherche		
	386	WO 94/01550 A1	01-20-1994	Hybridon, Inc.		
	387	WO 94/26764 A1	11-24-1994	Centre National de la Recherche		
	388	WO 96/11205 A1	04-18-1996	Isis Pharmaceuticals, Inc.		
	389	WO 97/26270 A2	07-24-1997	Ribozyme Pharm.		
	390	WO 97/30064 A1	08-21-1997	Stichting REGA		
	391	WO 97/46570 A1	12-11-1997	Isis Pharmaceuticals, Inc.		
	392	WO 98/16550 A1	04-23-1998	Isis Innovation Limited		
	393	WO 98/39352 A1	09-11-1998	Imanishi		
	394	WO 98/52614 A2	11-26-1998	The Board of Trustees of the Leland Stanford Junior Univ.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the them (book, magazine, journal, estail, symposium, catalog, etc.), date, page(s), Volume-issue Number(s), publisher, city and/or country where published.	Т
	395	Abe, A., et al., "Conformational energies and the random-coil dimensions and dipole moments of the polyoxides CH3O[CH2)yO]xCH3," J. Am. Chem. Soc., 1976, 98(21), 6468-6476	
	396	Afonina, I. et al., "Sequence-specific arrest of primer extension on single-stranded DNA by an oligonucleotide-minor groove binder conjugate," Proc. Natl. Acad. Sci. USA (1996) 93:3199-3204.	
	397	Agarwal, et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus" Proc. Natl. Acad. Sci. USA , 1988, 85, 7079-7083	
	398	Agarwal, et al., "Synthesis and Enzymatic Properties of Deoxyribooligonucleotides Containing Methyl and Phenylphosphonate Linkages", Nucleic Acid Research 1979, 6, 3009-3024	
	399	Agrawal, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?," Molecular Med. Today, Vol. 6(2), pages 72-81 (2000)	

Complete if Known Substitute for 1449/PTO **Application Number** 10/701,265 INFORMATION DISCLOSURE Filing Date 11-04-2003 STATEMENT BY APPLICANT First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 44 Attorney Docket Number ISIS-5300 Sheet 17

NON PATENT LITERATURE DOCUMENTS		
400	Agris, et al., "Inhibition of Vesicular Stomatitis Virus Protein Synthesis and Infection by Sequence-Specific Oligodeoxyribonucleoside Methylphosphonates", Biochemistry 1986, 25, 6268-6275	
401	Allerson, C.R. et al., Abstract of the 227th ACS National Meeting, Anaheim, CA, March 28- April 1, 2004	
402	Allerson, C.R. et al., "Fully 2'-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA," J. Med. Chem., 2005, 48, 901-904	
403	Altmann, KH. et al., "Second generation antisense oligonucleotides - inhibition of PKC-alpha and c-RAF kinase expression by chimeric oligonucleotides incorporating 6'-substituted carbocyclic nucleosides and 2'-O-ethylene glycol substituted ribonucleosides," Nucleosides & Nucleotides, 1997, 16(7-9), 917-926	
404	Altmann, KH., et al., "Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals," Chimia, 1996, 50, 168-176	
405	Altmann, K.H., et al., "Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors," Biochem. Soc. Trans., 1996, 24, 630-637	
406	Altschul, S.F. et al., "Basic Local Alignment Search Tool," J. Mol. Biol., 1990, 215, 403-410	
407	Ambros, V. et al., "A uniform system for MicroRNA annotation," RNA (2003) 9: 277-279	
408	Ambros, V. et al., "MicroRNAs and Other Tiny Endogenous RNAs in C. elegans, "Curr Biol. (2003) 13: 807-818	
409	Ambros, V. et al., "MicroRNAs: Tiny Regulators with Great Potential," Cell (2001) 107: 823-826	
410	Antopolsky, M. et al., "Peptide-Oligonucleotide Phosphorothioate Conjugates with Membrane Translocation and Nuclear Localization Properties," Bioconjuxate Chem. (1999) 10(4):598-606.	
411	Arar, K. et al., "Synthesis and Antiviral Activity of Peptide-Oligonucleotide Conjugates Prepared by Using Na-(Bromoaceytl)peptides," Bioconjugate Chem. (1995) 6(5):573-577.	
412	Arnott, S., et al., "Optimised parameters for A-DNA and B-DNA," Biochem. & Biophys. Res. Comm., 1972, 47(6), 1504-1510	
413	Asseline, U. et al., "Nucleic acid-binding molecules with high affinity and base sequence specificity: Intercalating agents covalently linked to oligodeoxynucleotides," Proc. Natl. Acad. Sci USA (1984) 81: 3297-3301	

Complete if Known Substitute for 1449/PTO **Application Number** 10/701,265 INFORMATION DISCLOSURE Filing Date 11-04-2003 STATEMENT BY APPLICANT First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 44 ISIS-5300 Sheet 18 Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
4	414	Astriab-Fisher et al., "Conjugates of antisense olgonucleotides with the TAT and antennapedia cell-penetrating peptides: effects on cellular update, binding to target sequences and biologic actions," Pharmaceutical Research (2002) 19(6): 744-754	
4	415	Astriab-Fisher, A. et al., "Antisense Inhibition of P-glycoprotein Expression Using Peptide- Oligonucleotide Conjugates," Biochem. Pharmacol. (2000) 60, 83-90.	
4	416	Baker, B. F. et al., "Oligonucleotide-europium complex conjugate designed to cleave the 5' cap structure of the ICAM-I transcript potentiates antisense activity in cells," Nucleic Acids Res. (1999) 27(6):1547-1551.	
4	1 17	Baker, B.F., et al., "2"-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells," J. Biol. Chem., 1997, 272(18), 11944-12000	
4	418	Bartel, B. et al., "MicroRNAs: At the Root of Plant Development," Plant Physiol. (2003) 132: 709-717	
4	419	Bayer, E. et al., "A New Support for Polypeptide Synthesis in Columns," Tetrahedron Letters, 1970, 51, 4503-4505	
4	420	Beaucage et al. "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives", (1993) Tetrahedron 49(10):1925-1963	
4	421	Beaucage S. and Iyer, R., "The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications", Tetrahedron, 1993, 49, 6123-6194	
4	122	Beaucage, S.L. et al., "Deoxynucleoside Phosphoramidites-A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,", Tetrahedron Letts., 1981, 22, 1859-1862	
4	123	Biggadike, et al., "Short convergent route to homochiral carbocylic 2'-deoxynucleosides and carbocyclic robonucleosides", J. Chem. Soc. Chem. Commun. 1987, 1083-1084	
4	124	Bollig, F. et a], "Affinity purification of ARE-binding proteins identifies poly(A)-binding protein 1 as a potential substrate in MK2-induced mRNA stabilization," Biochem. Bioophys. Res. Commun. (2003) 301: 665-670	
4	125	Bongartz, JP. et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," Nucleic Acids Res. (1994) 22(22):4681-4688.	
4	126	Bonora, G. M. et al., "Antisense activity of an anti-HIV oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycols," Farmaco (1998) 53:634-637.	
4	127	Bonora, G. M. et al., "Biological Properties of Antisense Oligonucleotides Conjugated to - Different High-Molecular Mass Poly(Ethy1en Glycols)," Nucleosides Nucleotides (1999) 18(687):1723-1725	

Complete if Known Substitute for 1449/PTO **Application Number** 10/701,265 INFORMATION DISCLOSURE Filing Date 11-04-2003 STATEMENT BY APPLICANT First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 19 44 ISIS-5300 Sheet Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS		
428	Bonora, G.M., et al., "A liquid-phase process suitable for large-scale synthesis of phosphorothioate oligonucleotides," Organic Process Res. & Develop., 2000, 225-231	
429	Borer, et al., "Stability of ribonucleic acid double-stranded helices," J. Mol. Biol., 1974, 86, 843-853	
430	Braasch et al., "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design," Nucleic Acids Research, 2002, 30, 5160-5167	
431	Braasch, D.A. et al., "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA," Chem Biol, 2001, 8, 1-7	
432	Braasch, D.A. et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," Biochemistry, 2003, 42, 7967-7975	
433	Braasch, D.A., et al., "Novel antisense and peptide nucleic acid strategies for controlling gene expression," Biochemistry, April 9, 2002, 41(14), 4503-4510	
434	Branda et al., "Amplification of antibody production by phosphorothioate oligodeoxynucleotides," J. Lab. Clin. Med., 1996, 128(3), 329-338	
435	Branden, L. J. et al., "A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA," Nature Biotech (1999) 17:784-787.	
436	Brazma, A., et al., "Gene expression data analysis," FEBS Lett., 2000, 480, 17-24	
437	Brill, et al., "Synthesis of Oligodeoxynucleoside Phosphorodithioates Via Thioamidites", J. Am. Chem. Soc. 1989, 111, 2321-2322	
438	Brown-Driver et al., "Inhibition of Translation of Hepatitis C Virus RNA by 2'-Modified Antisense Oligonucleotides," Antisense Nucleic Acid Drug Dev. (1999) 9(2): 145-154	
439	Buhr, C.A. et al., "Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza-2'-deoxyguanosine and 7-deaza-2'-deoxyadenosine," Nucleic Acids Research, 1996, 24(15), 2974-2980	
440	Butke, et al., "Facile synthesis of 2'amino-2deoxynucleoside from the corresponding arabino derivative," Nucleic Acid Chemistry, 1986, Part Three, 149-152	
441	Butler, M. et al., "Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice," Diabetes, 2002, 51, 1028-1034	
442	Caplen et al., "dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference," GENE (2000) 252: 95-105	

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FINANCE OF THE PROPERTY OF THE PROPERT

20

Compl	Complete if Known		
Application Number	10/701,265		
Filing Date	11-04-2003		
First Named Inventor	Brenda F. Baker		
Art Unit	1635		
Examiner Name	Jennifer S. Pitrak		
Attorney Docket Number	ISIS-5300		

	NON PATENT LITERATURE DOCUMENTS
443	Carulli, J.P., et al., "High throughput analysis of differential gene expression," J. Cellular Biochem. Suppl., 1998, 30(31), 286-296
444	Caruthers, M., "Synthesis of Oligonucleotides and Oligonucleotide Analogues", in "Oligonucleotides. Antisense Inhibitors of Gene Expression.", J.S. Cohen, Ed., CRC Press, Inc., 7-24, (1989)
445	Castle, et al., "Imidazo[4, 5-D]pyridazines. I. Synthesis of 4,7-disubstituted derivatives", Journal of Organic Chemistry, 1958, 23, 1534-1538
446	Cazalla, D. et al., "Nuclear Export and Retention Signals in the RS Domain of SR Proteins," Mol. Cell. Biol. (2002) 22(19):6871-6882.
447	Cazenave, C. et al., "Enzymatic amplification of translation inhibition of rabbit β-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents", Nucl. Acids Res., 1987, 15, 4717-4736
448	Celis, J.E., et al., "Gene expression profiling: monitoring transcription and translation production using DNA microarrays and proteomics," FEBS Lett., 2000, 480, 2-16
449	Cerutti, H., "RNA interference: traveling in the cell and gaining functions?" Trends in Genetics (2003) 19(1): 39-46
450	Chaloin, L. et al., "Design of Carrier Peptide-Oligonucleotide Conjugates with Rapid Membrane Translocation and Nuclear Localization Properties," Biochem. Biophys. Res. Commun. (1998) 243:601-608
451	Chaput, J.C., et al., "DNA polymerase-mediated DNA synthesis on a TNA template," J. Am. Chem. Soc., 2003, 125, 856-857
452	Chen and Wu, "Studies on Fluoroalkylation and Fluroalkoxylation. Part 33. Direct Trifluoromethylation of Aryl Halides with Fluorosulphonyldifluoromethyl lodide in the Presence of Copper: an Electron Transfer Induced Process," J. Chem. Soc., Perkin Transactions, 1989, 1, 2385-2387.
453	Chiang et al., "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms," J. Biol. Chem., 1991, 266, 18162-18171
454	Chirila, T.V. et al., "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides," Biomaterials, Vol. 23(2), pages 321-342 (2002)
455	Chiu et al., "siRNA function in RNAi: a chemical modification analysis," RNA, 2003, 9, 1034-1048
456	Chladek, et al., "Facile Synthesis of 2'Amino-2'Deoxyadenosine," J. Carbohydtrates, Necleosides & Nucleotides, 1980, 7, 63-75.

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Filing Date
First Named
Art Unit

Compl	Complete if Known		
Application Number	10/701,265		
Filing Date	11-04-2003		
First Named Inventor	Brenda F. Baker		
Art Unit	1635		
Examiner Name	Jennifer S. Pitrak		
Attorney Docket Number	ISIS-5300		

	NON PATENT LITERATURE DOCUMENTS	
457	Choung, S. et al., "Chemical modification of siRNAs to improve serum stability without loss of efficacy," Biochemical and Biophysical Research Communications, 2006, 342, 919-927	
458	Christofferson et al., "Ribozymes as human therapeutic agents", J. Med. Chem., 1995, 38(12), 2023-2037	
459	Chun-Nam Lok et al., "Potent gene-specific inhibitory properties of mixed backbone antisense oligonucleotides comprised of 2' -deoxy-2' -fluoro-D-arabinose and 2' -deoxyribose nucleotides," Biochemistry, 2002, 41, 3457-3467	
460	Cohen, G. L. et al., "Sequence Dependent Binding of cis-Dichlorodiamrnineplatinum(II) to DNA," J. Am. Chem. Soc. (1980) 102(7), 2487-2488.	
461	Constant et al., "Heterodimeric Molecules Including Nucleic Acid Bases and 9-Aminoacridine Spectroscopic Studies, Conformations, and Interactions with DNA", Biochemistry, 1988, 27, 3997-4003	
462	Conte, M.R., et al., "Conformational properties and thermodynamics of the RNA duplex r(CGCAAAUUUGCG)2: comparison with the DNA analogue d(CGCAAATTTGCG)2," Nucleic Acids Res., 1997, 25(13), 2627-2634	
463	Copy of PCT International Search Report dated January 24, 2005 (PCTUS03/35087)	
464	Corey, D. R. et al., "Generation of a Hybrid Sequence-Specific Single-Stranded Deoxyribonuclease," Science (1987) 238:1401-1403.	
465	Corey, D. R. et al., "Sequence-Selective Hydrolysis of Duplex DNA by an Oligonucleotide- Directed Nuclease," J. Am. Chem. Soc. (1989) 111(22):8523-8525.	
466	Corey, D. R., "48000-fold Acceleration of Hybridization by Chemically Modified Oligonucleotides," J. Am. Chem. Soc. (1995) 117(36):9373-9374.	
467	Cornell, W. D. et al., "A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules," J. Am. Chem. Soc., 1995, 117, 5179-5197	
468	Cossum, P.A. et al., "Disposition of the 14C-Labeled Phosphorothioate Oligonucleotide ISIS 2105 after Intravenous Administration to Rats," J. Pharmacol. Exp. Ther., 1993, 267(3), 1181-1190	
469	Couzin, J., "Small TNAs Make Big Splash," Science (2002) 298: 2296-2297	
470	Crawford, J.M., "Role of Vesicle-Mediated Transport Pathways in Hepatocellular Bile Secretion," Semin. Liver Dis., 1996, 16(2), 169-189	
471	Crooke, S.T., Antisense Research & Application, Chapter 1, Pages 1-50, Publ. Springer- Verlag, Ed. S.T. Crooke (1998).	

		Complete if Known			
Substitute for	1449/PTO			Application Number	10/701,265
	INFORMATION DISCLOSURE			Filing Date	11-04-2003
STA	STATEMENT BY APPLICANT			First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many sheets as necessary)			Examiner Name	Jennifer S. Pitrak
Sheet	Sheet 22 of 44		Attorney Docket Number	ISIS-5300	
•	•	•	•	•	•

NON PATENT LITERATURE DOCUMENTS	
472	Cummins, L.L. et al., "Characterization of fully 2'modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity," Nucleic Acids Research, 1995, 23(11), 2019-2024
473	Dahl, B.H. et al., "A Highly Reactive, Odourless Substitute for Thiphenol/Triethylmaine as a Deprotection Reagent in the Synthesis of Oligonucleotides and their Analogues," Acta Chem. Scand., 1990, 44, 639-641
474	Damha, et al., "Solution and solid phase chemical synthesis of arabinonucleotides", Can J. Chem., 1989, 831-839
475	Dande, P. et al., Abstract from The 227th ACS National Meeting, Anaheim, CA, March 28- April 1, 2004
476	De las Heras, et al., "3'-C-Cyano-3'-Deoxythymidine," Tetrahedron Letters, 1988, 29, 941-944
477	Dellinger, D.J. et al., "Solid-Phase Chemical Synthesis of Phosphonoacetate and Thiophosphonoacetate Oligodexynucleotides," J. Am. Chem. Soc., 2003, 125(4), 940-950
478	Denny, W.A., "DNA-intercalating ligands as anti-cancer drugs: prospects for future design," Anti-Cancer Drug Design, 1989, 4, 241-263
479	Dignam, et al., "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei," Nucleic Acids Res., 1983, 11, 1475-1489
480	Divakar, et al., "Approaches to the Synthesis of 2'-Thio Analogues of Pyrimidine Ribosides", J. Chem. Soc., Perkins Trans., I, 1990, 969-974
481	Divakar, et al., "Reaction Between 2,2'-Anhydro-1-β-D-arrabinofuranosyluracil and Thiolate lons", J. Chem. Soc., Perkins Trans. I, 1982, 1625-1628
482	Dreyer, et al., "Sequence-specific cleavage of single-stranded DNA: Oligodeoxynucleotide-EDTA-Fe(II)", Proc. Natl. Acad. Sci. USA, 1985, 82, 968-972
483	Duff, R. J. et al., "[17] Intrabody Tissue-Specific Delivery of Antisense Conjugates in Animals: Ligand-Linker-Antisense Oligomer Conjugates," Methods Enzymol. (2000) 313:297-321.
484	Eckstein, et al., "Polynucleotides Containing 2'Chloro-2'Deoxyribose", Biochemistry, 1972, 11, 4336-4344
485	Eddy, S.R., "Non-Coding RNA Genes and the Modern RNA World," Nature Rev. Genetics (2001) 2: 919-929
486	Efimov, V. A. et al., "Synthesis of Polyethylene Glycol - Oligonucleotide Conjugates," Bioorg. Khim. (1993) 19(8):800-804.

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 23 of

	NON PATENT LITERATURE DOCUMENTS	
		_
487	Egli, M. et al., "RNA Hydration: A Detailed Look," Biochemistry, 1996, 35, 8489-8494	
488	Elayadi, A.N. et al., "Application of PNA and LNA oligomers to chemotherapy," Curr. Opin. Investig. Drugs, 2001, 2(4), 558-561	
489	Elmén, J. et al., "Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality," Nucleic Acids Res. 2005, 33(1), 439-447	
490	EP Supplementary Search Report for EP 03716922 dated May 12, 2006	
491	Faria, M. et al., "Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo," Nature Biotech., 2001, 19, 40-44	
492	Fazakerley, G.V., et al., "A→Z transition in the synthetic hexanucleotide (dCdGfl)3," FEBS, 1985, 182(2), 365-369	
493	Fedoroff, O.Y. et al., "Structure of a DNA:RNA Hybrid Duplex," J. Mol. Biol., 1993, 233, 509-523	
494	Fieser, L. et al., Fieser and Fieser's Reagents for Organic Synthesis (1994), John Wiley & Sons, New York	
495	Fire et al., "RNA-triggered gene silencing," TIG (1999) 15(9): 358-363	
496	Firestone, R. A., "Low-Density Lipoprotein as a Vehicle for Targeting Antitumor Compounds to Cancer Cells," Bioconjugate Chern. (1994) 105-113.	
497	Flanagan, W. M. et al., "A cytosine analog that confers enhanced potency to antisense oligonucleotides," Proc. Natl. Acad. Sci. USA, Mar. 1999, 96, 3513-3518	
498	Flanagan, W.M. et al., "Cellular penetration and antisense activity by a phenoxazine- substituted heptanucleotide," Nature Biotechnol. (1999) 17(1): 48-52	
499	Fluiter, K. et al., "In vivo tumor growth inhibition and biodistribution studies of locked nucleic acids (LNA) antisense oligonucleotides," Nucleic Acids Res., 2003, 31(3), 953-962	
500	Fox, et al., "Nucleosides. XVIII. Synthesis of 2'-Fluorothymidine, 2'-Flurodeoxyuridine, and Other 2'-Halogeno-2'-Deoxy Nucleosides 12", J Org. Chem., 1964, 29, 558-564	
501	Francis, A.W. et al., "Probing the Requirements for Recognition and Catalysis in Fpg and Mut'y with Nonpolar Adenine Isosteres," J. Am. Chem. Soc. (2003) 125(52): 16235-16242	
502	Fraser, A., et al., "Synthesis and conformational properties of 2'-deoxy-2'-methylthiopyrimidine and -purine nucleosides:potential antisense applications," J. Heterocycl. Chem., 1993, 30, 1277-1287	

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 24 of

NON PATENT LITERATURE DOCUMENTS 503 Fraser, A.G. et al., "Functional genomic analysis of C. elegans chromosome 1 by systemic RNA interference." Nature, 2000, 408, 325-330 504 Freier, S. M. et al., "The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes," Nucleic Acids Research, 1997, 25(22), 4429-4443 Freskos. "Synthesis of 2'Deoxypyrimidine Nucleosides Via Copper (I) Iodine Catalysis," 505 Nucleosides & Nucleotides, 1989, 8, 1075, 1076 506 Frieden, M. et al., 'Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA." Nucleic Acids Res., 2003, 31(21), 6365-6372 507 Fromageot, H.P.M. et al., "The Synthesis of Oligonucleotides," Tetrahedron, 1967, 23, 2315-2331 508 Fuchs, B. et al., "Identification of Differentially Expressed Genes by Mutually Subtracted RNA Fingerprinting," Anal. Biochem., 2000, 286, 91-98 509 Gaffney, et al., "A New Strategy for the Protection of eoxyguanosine During Oligonucleotide Synthesis." Tetrahedron Letters, 1982, 23, 2257-2260 510 Gait, M.J. et al., "Application of chemically synthesized RNA," RNA: Protein Interactions (1998) Smith (ed.), pp. 1-36 511 Gait, M.J., "Oligoribonucleotides, Antisense Research and Applications, 1993, Crooke, S.T. and Lebleu, B. (eds.), CRC Press, Boca Raton, pp. 289-301 Gallo, M. et al., "2'-C-Methyluridine phosphoramidite: a new building block for the preparation 512 of RNA analogues carrying the 2'-hydroxyl group," Tetrahedron, 2001, 57(27), 5707-5713 Gao, J. et al., "Expanded-Size Bases in Naturally Sized DNA: Evaluation of Steric Effects in 513 Watson-Crick Pairing," J. Am. Chem. Soc. (2004) 126(38): 11826-11831 514 Geary, R.S. et al., "Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats, J. Pharmacol. Exp. Therap., 1998, 296(3), 890-897 515 Going, J.J., et al., "Molecular pathology and future developments," Eur. J. Cancer, 1999. 35(14), 1895-1904 516 Gonzalez, C, et al., "Structure and Dynamics of a DNA-RNA Hybrid Duplex with a Chral Phosphorothioate Moiety: NMR and Molecular Dynamics with Conventional and Time-Averaged Restraints," Biochemistry, 1995, 34, 4969-4982 517 Gorlach, M. et al., "The rnRNA Poly(A)-Binding Protein: Localization, Abundance, and RNABinding Specificity," Exp. Cells Res. (1994) 211:400-407

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Filing Date
First Namec
Art Unit

44

Sheet

Complete if Known		
Application Number	10/701,265	
Filing Date	11-04-2003	
First Named Inventor	Brenda F. Baker	
Art Unit	1635	
Examiner Name	Jennifer S. Pitrak	
Attorney Docket Number	ISIS-5300	

NON PATENT LITERATURE DOCUMENTS		
518	Graham, et al., "Tritium Labeling of Antisense Oligonucleotides by Exchange with Tritlated Water," Nucleic Acids. Res., 1993, 16, 3737-3743	
519	Graham, M.J. et al., "In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration," J. Pharmacol. Exp. Therap., 1998, 286(1), 447-458	
520	Gravert, D.J., et al., "Organic synthesis on soluble polymer supports," Chem. Rev., 1997, 97, 489-509	
521	Griffey, R.H. et al., "2"-O-Aminopropyl Ribonucleotides: A Zwitterionic Modification that Enhances the Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides," J. Med. Chem., 1996, 39(26), 5100-5109	
522	Griffin, B.E. et al., "The Synthesis of Oligoribonucleotides," Tetrahedron, 1967, 23, 2301-2313	
523	Grishok, A. et al., "Genetic Requirements for Inheritance of RNAi in C. elegans," Science, 2000, 287, 2494-2497	
524	Grünweller, A. et al., "Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA," Nucleic Acids Research, 2003, 31(12), 3185-3193	
525	Gryaznov, S. et al., "Oligodeoxynucleotide N3'P5' Phosphoramidates: Synthesis and Hybridization Properties," J. Am. Chem. Soc., 1994, 116(7), 3143-3144	
526	Guckian, K.M. et al., "Structure and Base Pairing Properties of a Replicable Nonpolar Isostere for Deoxyadenosine," J Org Chem (1998) 63(26):9652-9656	
527	Guillerm, D. et al., "Synthesis of 4'-fluoroadenosine as an inhibitor of S-adenosyl-L-homocysteine hydrolase," Bioorganic & Medicinal Chemistry Letters, 1995, 5(14), 1455-1460	
528	Guschlbauer, et al., "Nucleoside conformation is Determined by the Electronegativity of the Sugar Substituent," Nucleic Acids Res., 1980, 8, 1421-1433	
529	Guschlbauer, W. et al., "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic characterization and interaction with poly-inosinic acid," Nucleic Acid Research, 1977, 4(6),1933-1943	
530	Guschlbauer, W., et al., "Use of 2"-deoxy-2"-fluoro-necleosides in the study of polynucleotide conformation: a progress report," Nucleic Acid Research Symposium Series, 1982, 11,113-116	
531	Gutierrez, A.J. et al., "Antisense Gene Inhibition by C-5 Substituted Deoxyuridine-Containing Oligodeoxynucleotides," Biochemistry, 1997, 36(4), 743-748	

				Comp	ete if Known
Substitute for '	Substitute for 1449/PTO		Application Number	10/701,265	
	RMATION			Filing Date	11-04-2003
STAT	TEMENT E	BY APPLIC	CANT	First Named Inventor	Brenda F. Baker
				Art Unit	1635
	(use as many she	ets as necessary)		Examiner Name	Jennifer S. Pitrak
Sheet	26	of	44	Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
532	Guzaev, A. et al., "Conjugation of Oligonucleotides Via an Electrophilic Tether: N-Chloroacetarnidohexyl Phosphoramidite Reagent," Bioorg. Med. Chem. lett . (1998) 8:3671-3676.
533	Hakimelahi, G.H. et al., "High Yield Selective 3'-Silylation of Ribonucleosides," Tetrahedron Lett., 1981, 22(52), 5243-5246
534	Hall, J. et al., "Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides," Chem. Biol. (1994) 1(3):185-190.
535	Hamada et al., "Effects on RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3'Ends of siRNAs," Antisense and Nucleic Acid Drug Development (2002) 12:301-309
536	Hamilton et al., "A species of small antisense RNA in posttranscriptional gene silencing in plants," Science (1999) 286 (5441): 950-952
537	Hansske, et al., "2'and 3'-ketonucleosides and their arabino and XYLO reduction products," Tetrahedron, 1984, 40, 125-135
538	Hariton-Gazal, E. et al., "Targeting of Nonkaryophilic Cell-Permeable Peptides into the Nuclei of Intact Cells by Covalently Attached Nuclear Localization Signals," Biochemistry (2002) 41(29):9208-9214.
539	Harry O'Kuru, R.E. et al., "A Short, Flexible Route toward 2'-C-Branched Ribonucleosides," J. Org. Chem., 1997, 62(6), 1754-1759
540	Heasman, J., "Morpholino Oligos: Making Sense of Antisense?" Dev. Biol., 2002, 243, 209-214
541	Henderson, B. R. et al., "A Comparison of the Activity, Sequence Specificity, and CRM1- Dependence of Different Nuclear Export Signals," Exp. Cell Res. (2000) 256:213-224.
542	Hertel, et al., "Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides," J. Org. Chem., 1988, 53, 2406-2409.
543	Hill, F. et al., "Polymerase recognition of synthetic oligodeoxyribonucleotides incorporating degenerate pyrimidine and purine bases," Proc. Natl. Acad. Sci. USA, 1998, 95, 4258-4263
544	Hoffman, K., "Imidazole and its Derivatives" in The Chemistry of Heterocyclic Compounds, Weissberger, A., Ed.,Interscience Publishers, Inc., New York, 1953, 447
545	Holen, T., et al., "Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway," Nucleic Acids Res., 2003, 31(9), 2401-2407
546	Hornbeck, P. et al., Enzyme-Linked Immunosorbet Assays (ELIASE),* Curr. Protocols Mol. Biol., 1991, John Wiley & Sons, pp. 11.2.1-11.2.22

Complete if Known Substitute for 1449/PTO **Application Number** 10/701,265 INFORMATION DISCLOSURE Filing Date 11-04-2003 STATEMENT BY APPLICANT First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 44 Attorney Docket Number ISIS-5300

Sheet

	NON PATENT LITERATURE DOCUMENTS	
547	Hornung, V. et al., "Sequence-specific potent induction of IFN-a by short ineterfering RNA in plasmacytoid dendritic cells through TLR7," Nature Med., 2005, 11(3), 263-270	
548	Horton, N. C. et al., "The Structure of an RNA/DNA Hybrid: A Substrate of the Ribonuclease Activity of HIV-1 Reverse Transcriptase," J. Mol. Biol., 1996, 264, 521-533	
549	Huang, L. et al., "Oligonucleotide conjugates of Eu(III) tetraazamacrocycles with pendent alcohol and amide groups promote sequence-specific RNA cleavage," J Biol Inorg. Chem (2000) 5:85-92.	
550	Huh, N. et al., "Design, Synthesis, and Evaluation of Mitomycin-Tethered Phosphorothioate Oligodeoxynucleotides," Bioconjugate Chem. (1996) 7:659-669.	
551	Hunter, "Genetics: a touch of elegance with RNAi," Current Biology, Current Science (1999) 9(12): R440-R442	
552	Ikehara, et al, "Studies of Nucleosides and Nucleotides-LXV Purine Cyclonucleosides-26 A Versatile Method for the Synthesis of Purine O-Cyclo-Bucleosides. The First Synthesis of 8,2'Anhydro-8-Oxy 9-B-D-Arabinofuranosylguanine," Tetrahedron, 1975, 31, 1369-1372	
553	lkehara, et al, "Studies of Nucleosides and Nucleotides-LXXXVII. 1, Purine Cyclonucleosides. XLII. Synthesis of 2'deoxy-2'fluorofunaosine," Chem. And Pharm. Bull., 1981, 29, 1034-1038.	
554	lkehara, et al. "Purine cyclonucleosides. (43). Synthesis and properties of 2'halogen- 2'deoxyguanosines 1," Chem and Pharm Bull., 1981, 29, 3281-3285	
555	lkehara, et al., "A Linear Relationship Between Electronegativity of 2"-Substituents and Conformation of Adenine Nucleosides," Tetrahedron Letters, 1979, 42, 4073-4076	
556	Ikehara, et al., "Improved Synthesis of 2'-fluoro-2'deoxyadenosine and Synthesis and Carbon- 13 NMR Spectrum of its 3',5'-cyclic Phosphate Derivative," Nucleosides & Nucleotides, 1983, 2, 373-385	
557	lkehara, et al., "Polynucleotides. L. synthesis and properties of poly (2'chloro-2'-deoxyadenylic acid) and poly (2'-bromo-2'-deoxyadenylic acid)", Nucleic Acids Res., 1978, 4, 4249-4260	
558	Ikehara, et al., "Polynucleotides. LII. Synthesis and properties of poly (2'-deox-2'-fluoroadenylic acid)," Nucleic Acids Research, 1978, 5, 1877-1887	
559	Ikehara, et al., "Polynucleotides. LVI. Synthesis and Properties of Poly(2'-deoxy-2'-fluoroinosinic Acid)", Nucleic Acids Res., 1978, 5, 3315-3324	
560	Ikehara, et al., "Purine 8-Cyclonucleosides," Accts. Chem Res., 1969, 2, 47-53	

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

FIT

28

Compl	ete if Known
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS
561	Ikehara, et al., "Studies of Nucleosides and Nucleotides-LXXIV1 Purine Cyclonucleosides34 A New Method for the Synthesis of 2'-substituted 2'-deoxyadenosines," Tetrahedron, 1978, 34, 1133-1138
562	lkehara, et al., "Studies of Nucleosides and Nucleotides-LXXXII. 1 Cyclonucleosides. (39). 2 Synthesis and properties of 2'halogen-2'-deoxyadenosines," Chem. Pharm. Bull., 1978, 26, 2449-2453
563	lkehara, M., * 2-substituted 2*-deoxypurineucleotides their conformation and properties,* Heterocycles, 1984, 21(1), 75-90
564	Imazawa, et al., "Nucleosides and nucleotides. XII.1) Synthesis and properties of 2'-deoxy-2'-mercaptouridine and its derivates", Chem. Pharm. Bull., 1975, 23, 604-610
565	Incue et al., "Sequence dependent hydrolysis of RNA using modified oligonucleotide splints and Rnase H", FEBS Lett., 1987, 215(2), 327-330
566	Inoue, et al., "Synthesis and hybridization studies on two complementary nona(2'-O-methyl) ribonucleotides", Nucleic Acid Res., 1987, 15, 6131-6148
567	International Search Report Dated August 23, 2004 for International Application No. PCT/US03/09808
568	International Search Report dated March 24, 2005 for International Application No. PCT/US03/35088
569	International Search Report dated November 18, 2004 for International Application No. PCT/US03/29294
570	Jacobson, K.A. et al., "Methanocarba Analogues of Purine Nucleosides as Potent and Selective Adenosine Receptor Agonists," J. Med. Chem., 2000, 43(11), 2196-2203
571	Jäger, A. et al., "Oligonucleotide N-alkylphosphoramidates: Synthesis and binding to polynucleotides", Biochemistry 1988, 27, 7237-7246
572	Janik, B., et al., "Synthesis and Properties of Poly 2'-Fluoro-2'-Deoxyuridylic Acid," Biochem. Biophys. Res. Comm., 1972, 46(3), 1153-1160
573	Jarvi, et al., "Synthesis and biological evaluation of dideoxunucleosides containing a difluoromethylene unit", Nucleosides & Nucleotides, 1989, 8, 1111-1114
574	Jaschke, A. et al., "Synthesis and properties of oligodeoxyribonucleotide-polyethyleneg lycol conjugates," Nucleic Acids Res. (1994) 22(22):4810-4817.
575	Jayaraman, et al., "Selective Inhibition of Escherichia Coli Protein Synthesis and Growth by Nonionic Oligonucleotides Complementary to the 3' end of 16S rRNA", Proc. Natl. Acad. Sci. USA 1981, 78(3), 1537-1541

Complete if Known Substitute for 1449/PTO **Application Number** 10/701,265 INFORMATION DISCLOSURE Filing Date 11-04-2003 STATEMENT BY APPLICANT First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 44 Attorney Docket Number ISIS-5300 Sheet 29

	NON PATENT LITERATURE DOCUMENTS	
576	Jen et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells, 2000, 18, 307-319	_
577	Jones, et al., "4'-substituted nucleosides. 5. hydroxymethylation of nucleoside 5'-aldehydes", J. Org. Chem., 1979, 44, 1309-1317	
578	Jones, et al., "Transient protection: Efficient one-flask synthesis of protected deoxynucleosides", J. Am. Chem. Soc., 1982, 104, 1316-1319	
579	Jones, L.J. et al., "RNA Quantitation by Fluorescence-Based Solution Assay: RiboGreen Reagent Characterization," Anal. Biochem., 1998, 265, 368-374	
580	Jones, S.S. et al., "Migration of t-Butyldimethylsilyl Protecting Groups," J.C.S. Perkin 1, 1979, 2762-2764	
581	Juby, C. D. et al., "Facile Preparation of 3'0ligonucleotide-Peptide Conjugates," Tetrahedron Letters (1991) 32(7):879-882.	
582	Jungblut, P.R., et al., "Proteomics in human disease: cancer, heart and infectious diseases," Electrophoresis, 1999, 20, 2100-2110	
583	Jurecic, R., et al., "Long-distance DD-PCR and cDNA microarrays," Curr. Opin. Mocrobiol., 2000, 3, 316-321	
584	Kabanov, A.V.,"A new class of antivirals: antisense olgonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells", FEBS Letts., 1990, 259, 327-330	
585	Kawasaki, H/ et al., "Hesl is a target of MicroRNA-23 during retinoic-acid-induced neuronal differentation of NT2 cells," Nature (2003) 423: 838-842	
586	Khurshid et al., "The unique conformational stability of poly 2"-O-Ethyladenylic Acid," FEBS Letters, 1972, 28(1), 25	
587	Khvorova, A. et al., "Functional siRNAs Exhibit Strand Bias," Cell, 2003, 115(2), 209-216	
588	Kiaris, H. et al., "Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of U-87MG Human Gliobastoma in Nude mice," Neoplasia, 2000, 2(3), 242-250	
589	Kielanowska et al., "Preparation and properties of poly 2"-O-ethylcytidylic acid," Nucl. Acids Res., 1976, 3(3), 817-824	
590	Kingston, R.E. et al., "Calcium Phosphate Transfection", Current Protocols in Neuroscience, 1997, Supplement 1, A.1C.1 – A.1C.8	

Complete if Known Substitute for 1449/PTO **Application Number** 10/701,265 INFORMATION DISCLOSURE Filing Date 11-04-2003 STATEMENT BY APPLICANT First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 44 ISIS-5300 Sheet 30 Attorney Docket Number

	NON PATENT LITERATURE DOCUMENTS
591	Klopffer, A.E. et al., "Synthesis of 2'-Aminoalkyl-Substituted Fluorinated Nucleobases and Their Influence on the Kinetic Properties of Hammerhead Ribozymes," ChemBioChem (2004) 5: 707-716
592	Klopffer, A.E. et al., "The effect of universal fluorinated nucleobases on the catalytic activity of ribozymes," Nucleosides Nucleotides Nucleic Acids (2003) 22(5-8): 1347-1350
593	Knorre, et al., "Complementary-Addressed Sequence-Specific Modification of Nucleic Acids", Progress in Nucleic Acid Research and Molecular Biology 1985, 32, 291-321
594	Koole, et al., "Synthesis of phosphate-methylated DNA fragments using 9-fluorenylmethoxycarbonyl as transient base protecting group", J. Org. Chem., 1989, 54, 1657-1664
595	Koshkin, A.A., et al., "LNA (locked nucleic acid): an RNA mimic forming exceedingly stable LNA:LNA duplexes," J. Am. Chem. Soc., 1998, 120, 13252-13253
596	Koshkin, A.A., et al., "LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition," Tetrahedron, 1998, 54, 3607-3630
597	Kraynack, B.A. et al., "Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/elF2C2-dependent activity," RNA, 2006, 12, 163-176
598	Krieg, A. M. et al., "Uptake of Oligodeoxyribonucleotides by Lymphoid Cells Is Heterogeneous and Inducible," Antisense Research and Development (1991) 1:161-171.
599	Kroschwitz, J.I. (Ed.), The Concise Encyclopedia of Polymer Science and Engineering, John Wiley & Sons, 1990, 858-859
600	Krug, A., et al., "Synthesis of oligonucleotide probes containing 2'-deoxy-2'-fluoronucleosides for cleavage of RNA by RNase H," Biomed. Biochem. Acta, 1990, 49, 161-166
601	Krug, A., et al., "The behaviour of 2'-deoxy-2'-fluorouridine incorporated into oligonucleotides by the phosphoramidite approach," Nucleosides & Nucleotides, 1989, 8(8), 1473-1483
602	Kuijpers, W. H. A. et al., "Specific Recognition of Antibody-Oligonucleotide Conjugates by Radiolabeled Antisense Nucleotides: A Novel Approach for Two-Step Radioimmunotherapy of Cancer," Bioconjugate Chem. (1993) 4(1):94-102.
603	Kumar et al., "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes," Microbiology and Molecular Biology Reviews (1998) 62(4): 1415-1434
604	Kumar, R., et al., "The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA," Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222

Substitute for 1449/PTO

INFORMATION DISCLOSURE

Sheet

(use as many sheets as necessary)

31 of

STATEMENT BY APPLICANT

NON PATENT LITERATURE DOCUMENTS 605 Kurchavov, N.A., et al., "A new phosphoramidite reagent for the incorporation of diazaphenoxazinone nucleoside with enhanced base-pairing properties into oligodeoxynucleotides," Nucleosides and Nucleotides, 1997, 16, 1837-1846 606 Kurreck, J., "Antisense technologies, Improvement through novel chemical modifications," Eur. J. Biochem., 2003, 270(8), 1628-1644 Kusmierek et al., "Alkvation of cytidine-5'-phosphate: Mechanisms of alkylation, influence of 607 O'-alkylation on susceptibility of pyrimidine nucleotides to some nucleolytic enzymes, and synthesis of 2'-O-alkyl polynucleotides," ACTA Biochim. Polonica, 1973, 20(4), 365-381 Lacerra, G., et al., "Restoration of hemoglobin a synthesis in erythroid cells from peripheral 608 blood of thalassemic patients," Proc. Natl. Acad. Sci. USA, August 15, 2000, 97(17), 9591-9596 609 Lai J. S. et al.. "Fluorinated DNA Bases as Probes of Electrostatic Effects in DNA Base Stacking," Angew. Chem. Int. Ed. (2003) 42: 5973-5977 610 Lai, J. S. et al., "Selective Pairing of Polyfluorinated DNA Bases," J. Am. Chem. Soc. (2004) 126(10): 3040-3041 611 Lane, A. N. et al., "NMR Assignments and Solution Conformation of the DNA-RNA Hybrid Duplex d(GTGAACTT)-r(AAGUUCAC)," Eur. J. Biochem., 1993, 215, 297-306 612 Larson, E.J., et al., "Rapid DNA fingerprinting of pathogens by flow cytometry," Cytometry, 2000, 41, 203-208 613 Larsson, M., et al., "High-throughput protein expression of cDNA products as a tool in functional genomics," J. Biotechnol., 2000, 80, 143-157 614 Le Doan et al., "Sequence-Targeted Chemical Modifications of Nucleic Acids by Complementary Oligonucleotides Covalently Linked to Porphyrins", Nucleic Acid Research, 1987, 15, 8643-8659 615 Lee, R.C. et al., "The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14," Cell, 1993, 75(5), 843-854 616 Lee, K, et al., "Ring-Constrained (N)-Methanocarba Nucleosides as Adenosine Receptor Agonists: Independent 5'-Uronamide and 2'-Deoxy Modifications," Bioorganic & Medicinal Chemistry Letters, 2001, 11(10), 1333-1337 617 Lee, Y. et al., "MicroRNA maturation: stepwise processing and subcellular localization," EMBO J. (2002) 21(17): 4663-4670 618 Lee, Y, et al., "The nuclearRNase III Drosha initiates microRNA processing," Nature (2003) 425: 415-419

0.1.111.1.6.1110.0000	Compl
Substitute for 1449/PTO	Application Number
INFORMATION DISCLOSURE	Filing Date
STATEMENT BY APPLICANT	First Named Inventor
	Art Unit
(use as many sheets as necessary)	Examiner Name

of

44

Sheet

Complete if Known	
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS	
619	Leeds, J.M. et al., "Pharmacokinetic Properties of Phosphorothioate Oligonucleotides," Nucleosides Nucleotides, 1997, 16(7-9), 1689-1693	
620	Letsinger et al., "Effects of Pendant Groups at Phosphorus on Binding Properties of D-ApA Analogues", Nucleic Acids Research, 1986, 14, 3487-3499	
621	Letsinger, R.L. et al., "Cholesteryl-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture", Proc. Natl. Acad. Sci., 1989, 86, 6553-6556	
622	Lewis, D.L. et al., "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," Nature Genetics, 2002, 32, 107-108	
623	Li, S. et al., "Folate-Mediated Targeting of Antisense Oligodeoxynucleotides to Ovarian Cancer Cells," Pharm. Res. (1998) 15(10):1540-1545.	
624	Lima, W. F. et al., "Highly efficient endonucleolytic cleavage of RNA by a CyszHisz zinc-finger peptide," Proc. Natl. Acad. Sci. USA (1999) 96:10010-10015.	
625	Lima, W.F. et al., "Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids," Biochemistry, Vol. 36, pages 390-398 (1997)	
626	Limbach, P.A. et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Res., 1994, 22(12), 2183-2196	
627	Lin, KY. et al., "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acids," J. Am. Chem. Soc., 1998, 120(33), 8531-8532	
628	Lin, KY. et al., "Tricyclic 2"-Deoxycytidine Analogs: Synthesis and Incorporation into Oligodeoxynucleotides Which Have Enhanced Binding to Complementary RNA," J. Am. Chem. Soc., 1995, 117, 3873-3874	
629	Lin, M. et al., "Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in dermal fibroblasts," Faseb J. 1995, 9, 1371-1377	
630	Liu, H. et al."A Four Base Paired Genetic Helix with Expanded Size," Science (2003) 302; 868-871	
631	Liu, H. et al., "Toward a New Genetic System with Expanded Dimensions: Size-Expanded Analogues of Deoxyadenosine and Thymidine," J. Am Chem Soc. (2004) 126(4) 1102-1109	
632	Liu, K. et al., "Efficient Nuclear Delivery of Antisense Oligodeoxynucleotides and Selective Inhibition of CETP Expression by Apo E Peptide in a Human CETP-Stably Transfected CHO Cell Line," Arterioscler. Thromb. Vasc. Biol. (1999) 19:2207-2213.	

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

33

Compl	ete if Known
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

NON PATENT LITERATURE DOCUMENTS	
633	Lixin, R. et al., "Novel Properties of the Nucleolar Targeting Signal of Human Angiogenin," Biochem. Biophys. Res. Comm. (2001) 284:185-193.
634	Loakes, D. et al., "The applications of universal DNA base analogues," Nucleic Acids Res., 2001, 29(12), 2437-2447
635	Lukhtanov, E. A. et al., "Direct, Solid Phase Assembly of Dihydropyrroloindole Peptides with Conjugated Oligonucleotides," Bioconjugate Chem. (1996) 7(5):564-567.
636	Madden, S.L., et al., "Serial analysis of gene expression: from gene discovery to target identification," Drug Discov. Today, September 2000, 5(9), 415-425
637	Mahato et al., "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA," Expert Opinion on Drug Delivery, Jan. 2005, 2(1), 3-28
638	Manche et al., "Interactions between double-stranded RNA regulators and the protein kinase DAI," Mol. Cell Biol., 1992, 12(11), 5238-5248
639	Manoharan M. et al., "Cholic Acid-Oligonucliotide Conjugates for Antisense Applications", Bioorganic Med. Chem. Letts., 1994, 4, 1053-1060
640	Manoharan M. et al., "Oligonucleotide Conjugates: Alteration of the Pharmacokinetic Properties of Antisense Agents", Nucleosides and Nucleotides, 1995, 14, 969-973
641	Manoharan, M. et al., "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides", Annals NY Acad. Sciences, 1992, 660, 306-309
642	Manoharan, M. et al., "Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications", Bioorg. Med. Chem. Letts., 1993, 3, 2765-2770
643	Manoharan, M. et al., "Novel Functionalization of the Sugar Moiety of Nucleic Acids for Multiple Labeling in the Minor Groove," Tetrahedron Letters (1991) 32(49):7171-7174.
644	Manoharan, M. et al., "Lipidic Nucleic Acids", Tetrahedron Letts., 1995, 36, 3651-3654
645	Manoharan, M., "2"-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation," Biochimica et Biophysica Acta, 1999, 1489, 117-130
646	Manoharan, M., "Designer Antisense Oligonucleotides: Conjugation Chemistry and Functionality Placement," Antisense Research and Applications, Crooke and Lebleu, eds., CRC Press Boca Ration. Ft. 1993, Chapter 17, 303-349.

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Toxicol., 1989, 5(2), 201-206

Complete if Known				
Application Number	10/701,265			
Filing Date	11-04-2003			
First Named Inventor	Brenda F. Baker			
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

	NON PATENT LITERATURE DOCUMENTS				
647 Manoharan, M., "Oligonucleotide Conjugates as Potential Antisense Drugs with Im Uptake, Biodistribution, Targeted Delivery and Mechanism of Action," Antisense & I Acid Drug Development (2002) 12:103-128.					
648	Manoharan, M., "Oligonucleotide Conjugates in Antisense Technology," Antisense Drug Technology, Principles, Strategies, and Applications, Crooke, S. T. ed., Marcel Dekker, New York, (2001) Chapter 16, 391-467.				
649	Manoharan, M., "RNA interference and chemically modified small interfering RNAs," Current Opinion in Chemical Biology, 2004, 8, 570-579				
650	Marcus-Sekura, "Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages", Nucleic Acids Res., 1987, 15, 5749-5763				
651	Marcus-Sekura, "Techniques for Using Antisense Oligodeoxyribonucleotides to Study Gene Expression", Anal. Biochemistry, 1988, 172, 289-295				
652	Markiewicz, et al., "Simultaneous Protection of 3'- and 5'-Hydroxyl Groups of Nucleosides", Nucleic Acid Chemistry, Part 3, pgs. 229-231, L.B. Townsend, et al., Eds., J. Wiley and Sons, New York, 1986, 229-231				
653	Maruenda, H. et al., "Antisense Sequence-Directed Cross-Linking of DNA Oligonucleotides by Mitomycin C," Bioconjugate Chem. (1996) 7(5):541-544.				
654	Maruenda, H. et al., "Antisense sequence-directed cross-linking of RNA oligonucleotides by mitomycin," Anti-Cancer Drug. Des. (1997) 12, 473-479				
655	Marwick, C., "First "Antisense" Drug Will Treat CMV Retinitis," J. Am. Med. Assoc., 1998, 280(10), 871				
656	Matsukura, M. et al., "Phosphorothicate Analogs of Oligodeoxynucleotides: Inhibitors of Replication and Cytopathic Effects of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA, 1987, 84, 7706-7710				
657	Matteucci, M.D. et al., "Synthesis of Deoxyoligonucleotides on a Polymer Support," J. Am. Chem. Soc., 1981, 103(11), 3185-3191				
658	McCafferey, A.P. et al., "RNA interference in adult mice," Nature, 2002, 418, 38-39				
659	McIntyre, K.W. et al., "A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-kB p65 Causes Sequence-Specific Immune Stimulation," Antisense Res. Dev., 1993, 3, 309-322				
660	McQueen, C.A. et al., "Effect of Nalidixic Acid on DNA Repair in Rat Hepatocytes," Cell Biol.				

Complete if Known Substitute for 1449/PTO **Application Number** 10/701,265 INFORMATION DISCLOSURE Filing Date 11-04-2003 STATEMENT BY APPLICANT First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 44 Attorney Docket Number ISIS-5300

Sheet

	NON PATENT LITERATURE DOCUMENTS				
661 Meunier, L. et al., "The nuclear export signal-dependent localization of oligonucleopepti enhances the inhibition of the protein expression from a gene transcribed in cytosol," N Acids Res. 1999, 27(13):2730-2736					
662	Meyer, et al., "Efficient, Specific Cross-Linking and Cleavage of DNA by Stable, Synthetic Complementary Oligodeoxynucleotides", J. Am. Chem. Soc. 1989, 111, 8517-8519				
663 Mili, S. et al., "Distinct RNP Complexes of Shuttling hnRNP Proteins with Pre-mRNA rnRNA. Candidate Intermediates in Formation and Export of mRNA," Mol. Cell Biol. (2 21(21):7307-7319.					
664 Miller, et al., "A New Approach to Chemotherapy Based on Molecular Biology and Nuclei Acid Chemistry: Matagen (Masking Tape for Gene Expression", Anti-Cancer Drug Design 1987, 2, 117-128					
665 Miller, et al., "Biochemical and Biological Effects of Nonionic Nucleic Acid Methylphosphonates", Biochemistry 1981, 20, 1874-1880					
666 Miller, et al., "Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates", Biochemistry 1979, 18, 5134-5143					
667	Miller, et al., "Synthesis and properties of adenine and thymine nucleoside alkyl phosphotriesters, the neutral analogs of dinucleoside monophosphates", J. Am. Chem. Soc. 1971, 93, 6657-6664				
668 Min, KL. et al., "Oligonucleotides comprised of alternating 2' -deoxy-2' -fluoro-beta-D- arabinonucleosides and D-2' -deoxyribonucleosides (2"F-ANA/DNA 'Altimers') induce effi RNA cleavage mediated by RNase H," Bioorganic & Medicinal Chemistry Letters, Septer 2002, 12, 2651-2654					
669 Mishra et al., "Improved leishmanicidal effect of phosphoroticate antisense oligonucleotid by LDL-medicated delivery", Biochim. Biophys. Acta, 1995, 1264, 229-237					
670 Miura et al., "Fluorometric determination of total mRNA with oligo(dT) immobized on m plates", Clin. Chem., 1996, 42(11), 1758-1764					
671 Moran, S. et al., "A thymidine triphosphate shape analog lacking watson-crick pairing a replicated with high sequence selectivity," Proc. Natl. Acad. Sci. USA (1997) 94, 10506					
672	Moran, S. et al., "Difluorotoluene, a Nonpolar Isostere for Thymine, Codes Specifically and Efficiently for Adenine in DNA Replication," J Am Chem Soc. (1997) 119(8), 2056-2057				
673	Morita, K. et al., "2'-O,4'-C-Ethylene-Bridged Nucleic Acids (ENA): Highly Nuclease-Resistant and Thermodyamically Stable Oligonucleotides for Antisense Drug," Bioorganic & Medicinal Chemistry Letters, 2002, 12(1), 73-76				

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

First Named I

Art Unit

Complete if Known				
Application Number	10/701,265			
Filing Date	11-04-2003			
First Named Inventor	Brenda F. Baker			
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

	NON PATENT LITERATURE DOCUMENTS			
674 Morita, K. et al., "Synthesis and Properties of 2"-0,4"-C-Ethylene-Bridged Nucleic Acids (as Effective Antisense Oligonucleotides," Bioorg. Med. Chem., 2003, 11, 2211-2226				
675	Moulds, C. et al., "Site and Mechanism of Antisense Inhibition by C-5 Propyne Oligonucleotides," Biochemistry, 1995, 34(15), 5044-5053			
676	Nasevicius, A. et al., "Effective targeted gene 'knockdown' in zebrafish," Nature Genetics, 2000, 26, 216-220			
677	NELSON, P. S. et al., "Bifunctional oligonucleotide probes synthesized using a novel CPG support are able to detect single base pair mutations," Nucleic Acids Res. (1989) 17(18):7187-7194			
678 Nestle, F.O. et al., "Cationic Lipid is not Required for Uptake and Selective Inhibitory of ICAM-1 Phosphorothioate Antisense Oligonucleotides in Keratinocytes," J. Invest. Dermatol., 1994, 103, 569-575				
679	Nielsen et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide", Science, 1991, 254, 1497-1500			
680 Nykänen, A. et al, "ATP Requirements and Small Interfering RNA Structure in the RN. Interference Pathway," Cell, 2001, 107, 309-321				
681 Oberhauser et al., "Effective incorporation of 2'-O-methyl-oligonucleotides into lipos enhanced cell association through modification with thiocholesterol", Nucl. Acids Rd 20(3), 533-538				
682 Ogilvie, K.K. et al., "The Use of Silyl Groups in Protecting the Hydroxyl Functions of Ribonucleosides," Tetrahedron Letters, 1974, 15(33), 2861-2863				
683 Ohtsuka et al., "Recognition By Restriction Endonuclease EcoRI of Deoxyoctanucleotid containing modified sugar moieties," Eur. J. Biochem., Mar. 1984, 447-450				
684 Olie, R.A. et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bd-2/bd-xL antisense oligonucleotide," Biochimica et Biophysica Acta, 1576 (2002), 101-109				
685 Olsen, D.B., et al., "Study of a Hammerhead Ribozyme Containing 2"-Modified Adenosis Residues," Biochemistry, 1991, 30:, 9735-9741				
686 O'Neill, B.M. et al., "A Highly Effective Nonpolar Isostere of Deoxyguanosine: Synthesis, Structure, Stacking, and Base Pairing," J. Org. Chem. (2002) 67(17):5869-5875				
687	Opalinska et al., "Nucleic-acid therapeutics: basic principles and recent applications," Nature Review, 2002, 1, 503-514			
688	Ørum, H. et al., "Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development," Curr. Opin. Mol. Therap., 2001, 3(3), 239-243			

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as perassar)

(use as many sheets as perassar)

Examiner Name

Jennifer S. Pitrak

Examiner Name

Learning Many Services (South Robert South Robert

Sheet

37

44

Attorney Docket Number

ISIS-5300

	NON PATENT LITERATURE DOCUMENTS					
689	Outten, et al., "Synthetic 1-methoxybenzo[d]naphtho[1,2-b]pyran-6-one c-glycosides", J. Org. Chem. 1987, 52, 5064-5066					
690	Owen, et al., "Transcriptional activation of a conserved sequence element by ras requires a nuclear factor distinct from c-fos or c-jun", Proc. Natl. Acad. Sci USA, 1990, 87, 3866-3870					
691	Owen, G.R. et al., "4'-Substituted Nucleosides. 3. Synthesis of Some 4'-Fluorouridine Derivatives," J. Org. Chem., 1976, 41(18), 3010-3017					
692	Parker, J.S. et al., "Structure insights into mRNA recognition from a PIWI domain-siRNA guic complex," Nature, 2005, 434, 663-666					
693	Parkes, et al., "A short synthesis of 3'-cyano-3'-Deoxythymidine", Tetra. Lett., 1988, 29, 2995-2996					
694	Parr, W. et al., "Solid-Phase Peptide Synthesis on an Inorganic Matrix having Organic Groups on the Surface," Angew Chem. Internat. Edit, 1972, 11 (4), 314-315					
695	Patzel et al., "A Theoretical Approach to Select Effective Antisense Oligodeoxyribonucleotides at High Statistical Probability," Nucleic Acids Research (1999) pp. 4328-4334.					
696	Peracchi, A., "Prospects for antiviral ribozymes and deoxyribozymes," Rev. Med. Virol., Vol. 14, pages 47-64 (2004). Petersen, M. et al., "The conformations of locked nucleic acids (LNA)," J. Mol. Recognit., 2000, 13, 44-53					
697						
698	Petersheim, et al., "Base-Stacking and Base-Pairing contributions to helix stability: thermodynamics of double-helix formation with CCGG, CCGGp, CCGGAp, ACCGGp, CCGGUp, and ACCGGUp", Biochemistry, 1983, 22, 256-263					
699	Pichon, C. et al., "Intracellular Routing and Inhibitory Activity of Oligonucleopeptides Containing a KDEL Motif," Mol. Pharmacol. (1997) 51:431-438.					
700	Pieken, W.A., et al., "Structure-Function Relationship of Hammerhead Ribozymes as Probed by 2'-Modifications," Nucleic Acids Symp Ser., 1991, 24, 51-53					
701	Pike et al., "Mixed Alkylation (Methylation and Ethylation) of Adenosine by Diazoethane in Aqueous 1,2-Dimethoxyethane," J. Org. Chem., 1974, 39(25), 3674-3676					
702	Pitts, A.E. et al., "Inhibition of human telomerase by 2'-O-methyl-RNA," Proc. Natl. Acad. Sci. USA, 1998, 95, 11549-11554					
703	Poopeiko, N.E. et al., "Xylo-configured Oligonucleotides (XNA, Xylo Nucleic Acid): Synthesis of Conformationally Restricted Derivatives and Hybridization Towards DNA and RNA Complements," Biorganic & Medicinal Chemistry Letters 2003, vol. 13, pages 2285-2290					

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet

(use as many sheets as necessary)
38 of

Complete if Known				
Application Number	10/701,265			
Filing Date	11-04-2003			
First Named Inventor	Brenda F. Baker			
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

NON PATENT LITERATURE DOCUMENTS 704 Prakash, T. P. et al., Abstract of The 227th ACS National Meeting, Anaheim, CA, March 28-April 1, 2004 705 Prakash, T. P. et al., "Synthesis of Site-Specific Oligonucleotide-Polyamine Conjugates," Bioorg, Med. Chem. Lett. (1994) 4(14):1733-1738. 706 Prashar, Y., et al., "A method for display of 3'-end fragments of restriction enzyme-digested cDnAs for analysis of differential gene expression," Methods Enzymol., 1999, 303, 258-272 707 Puglisi, et al., "Absorbance melting curves of RNA", Methods in Enzymology, 1989, 180, 304-325 708 Raiur, S. B. et al., "Covalent Protein-Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules," Bioconjugate Chem. (1997) 8(6):935-940. 709 Ranganathan, "Modification of the 21-Position of Purine Nucleosides; Synthesis of 21-a-Substituted-21-Deoxyadenosine Analogs", Tetrahedron Letters, 1977, 15, 1291-1294 710 Ransford et al., "2'-O-Ethyl Pyrimidine Nucleosides," J. Carbohydrates - Nucleosides -Nucleotides, 1974, 1(3), 275-278 Rao, et al., "A Novel One-step Procedure for the Conversion of Thymidine into 2,3'-711 Anhydrothymidine", J. Chem. Soc. Chem. Commun., 1989, 997-998 712 Rausch, J.W. et al., "Hydrolysis of RNA/DNA hybrids containing nonpolar pyrimidine isosteres defines regions essential for HIV type 1 polypurine tract selection," PNAS (2003) 100(20): 11279-11284 713 Reddy, M.P. et al., "Fast Cleavage and Deprotection of Oligonucleotides," Tetrahedron Letters, 1994, 35(25), 4311-4314 714 Reese, C.B., et al., "4-(1,2,4-Triazol-1-vl)-and 4-(3-Nitro-1,2,4-triazol-1-vl)-1-(β-D-Arabinofuranosyl)cytosine(Ara-C)", J. Chem. Soc. Perkin Trans. I, 1982, pgs. 1171-1176 715 Renneberg, D. et al. "Antisense properties of tricyclo-DNA." Nucleic Acids Res., 2002, 30(13), 2751-2757 716 Renneberg, D., et al., "Watson—Crick base-pairing properties of tricycle-DNA." J. Am. Chem. Soc., 2002, 124, 5993-6002 717 Revankar et al., "Synthesis and Antiviral/Antitumor of Certain 3-Seazaguanine Nucleosides and Nucleotides", J. Med. Chem. 1984, 24, 1389-1396 718 Rhodes, J. et al., "Therapeutic potentiation of the immune system by costimulatory Schiff-

baseforming drugs," Nature (1995) 377(6544):71-75.

Substitute for 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

First

Complete if Known				
Application Number	10/701,265			
Filing Date	11-04-2003			
First Named Inventor	Brenda F. Baker			
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

	NON PATENT LITERATURE DOCUMENTS			
719	Robins, et al., "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides", J. Am. Chem. Soc., 1983, 105, 4059-4065			
720	Robins, et al., "Synthesis of 2'-Deoxytubercidin, 2'-Deoxyadenosine, and Related 2'-Deoxynucleosides via a Novel Direct Stereospecific Sodium Salt Glycosylation Procedure", J. Am. Chem. Soc., 1984, 106, 6379-6382			
721	Roelen et al., "Synthesis of Nucleic Acid Methylphos-Phonothioates", Nucleic Acids Research 1988, 16(15), 7633-7645			
722	Rottman et al., "Influence of 2'-O-Alkylation on the Structure of Single-Stranded Polynucleotides and the Stability of 2'-O-Alkylated Polynucleotide Complexes," Biochem., 1974, 13, 2762-2771			
723	Ruby, et al., "An Early Hierarchic Role of U1 Small Nuclear Ribonucleoprotein in Splicesome Assembly", Science, 1988, 242, 1028-1035			
724	Rump, E. T. et al., "Preparation of Conjugates of Oligodeoxynucleotides and Lipid Structures and Their interaction with Low-Density Lipoprotein," Bioconjugate Chem. (1998) 9(3):341-349.			
725	Ryan, et al., "Synthesis of 2-Thio-D-ribose and 2'-Thioadenosine Derivatives", J. Org. Chem., 1971, 36(18), 2646-2657			
726	Sambrook, et al., "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Laboratory Press, 1989, Vol. 2, pgs. 11.31-11.32			
727	San et al., "Safety and short term toxicity of a novel cationic lipid formulation for human gene therapy", Human Gene Therapy, 1993, 4, 781-788			
728	Sanghvi, Y.S. et al., "Heterocyclic Base Modifications in Nucleic acids and their Applications in Antisense Oligonucleotides", Antisense Research and Applications, CRC Press, Boca Raton, Chapter 15, 1993, 273-288			
729	Scaringe, S.A. et al., "Novel RNA Synthesis Method Using 5'-O-Silyl-2'-O-orthoester Protecting Groups," J. Am. Chem. Soc., 1998, 120(45), 11820-11821			
730	Scaringe, S.A., "RNA Oligonucleotide Synthesis via 5'-Silyl-2'-Orthoester Chemistry," Methods, 2001, 23, 206-217			
731	Scaringe, S.A., Thesis entitled, "Design and Development of New Protecting Groups for RNA Synthesis," University of Colorado (1996)			
732	Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," Nat. Biotechnol., 2003, 21(12), 1457-1465			

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Art Unit

Application Num
Filing Date
First Named Inv
Art Unit

44

Sheet

Complete if Known				
Application Number	10/701,265			
Filing Date	11-04-2003 Brenda F. Baker			
First Named Inventor				
Art Unit	1635			
Examiner Name	Jennifer S. Pitrak			
Attorney Docket Number	ISIS-5300			

NON PATENT LITERATURE DOCUMENTS					
733	Schöning, KU., et al., "Chemical etiology of nucleic acid structure: the α-threofuranosyl-(3'→2') oligonucleotide system," Science, 2000, 290, 1347-1351				
734	Schwartz, et al., "A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity", Gene, 1990, 88, 197-205				
735	Schwartz, M.E. et al., "Rapid Synthesis of Oligoribonucleotides Using 2'-O-(o- Nitrobenzyloxymethyl)-Protected Monomers," Bioorg, Med. Chem. Lett., 1992, 2(9), 1019- 1024				
736	Schwarz, D.S. et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," Cell, 2003, 115(2), 199-208				
737	Searle, M. S. et al., "On the Stability of Nucleic Acid Structures in Solution: Enthalpy-Entropy Compensations, Internal Rotations and Reversibility," Nucl. Acids Res., 1993, 21(9), 2051-2056				
738	Seela, et al., "Palindromic Octa- and Dodecanucleotides Containing 2-Deoxytubercidin: Synthesis, Hairpin Formation, and Recognition by the Endodeoxyribonuclease", Biochemistry, 1987, 26, 2232-2238				
739	Seliger, H., et al., "Synthetic Oligonucleotides for Biomedical Applications," Nucleic Acids Symp Ser., 1991, 24:193-196				
740	Shea et al., "Synthesis, hybridization properties and antiviral activity of lipid- oligodeoxynucletide conjugates", Nucl. Acids Res., 1990, 18(13), 3777-3783				
741 Sheehan, D. et al., "Biochemical properties of phosphonoacetate and thiophosphologodeoxyribonucleotides," Nucleic Acids Res., 2003, 31(14), 4109-4118					
742 Shi, Y., "Mammalian RNAi for the masses," Trends in Genetics (2003) 19(1): 9-					
743	Sigman, "Nuclease Activity of 1,10-Phenanthroline-Copper Ion", Acc. Chem. Res., 1986, 19, 180-186				
744	Singer et al., "Alkylation of Ribose in RNA Reacted with Ethylnitrosourea at Neutrality," Biochem., 1976, 15(23), 5052				
 745 Singh, S.K. et al., "LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition," Chem. Commun., 1998, 4, 455-456 746 Singh, S.K., et al., "Synthesis of 2"-amino-LNA: a novel conformationally restricted hig oligonucleotide analogue with a handle," J. Org. Chem., 1998, 63, 10035-10039 					
747	Skorski, T. et al., "Antileukemia effect of c-myc N3'P5' phosphoramidate antisense oligonucleotides in vivo," Proc. Natl. Acad. Sci. USA, 1997, 94, 3966-3971				

	0.1.111.1.1.1.1110.				Coi
	Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
	(use as many sheets as necessary)			Examiner Name	
	Sheet	41	of	44	Attorney Docket Number

Complete if Known	
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS	
748	Smith et al., "Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5", Proc. Natl. Acad. Sci. USA, 1986, 83, 2787-2791	
749	Smith, T.F. et al., "Comparison of Biosequences," Adv. Appl. Math., 1981, 2, 482-489	
750	Song, E. et al., "RNA interference targeting Fas protects mice from fulmiant hepatitis," Nature Med., 2003, 9(3), 347-351	
751	Song, JJ. et al., "The Crystal Structure of Argonaute and Its Implication for RISC Slicer Activity," Science, 2004, 305, 1434-1437	
752	Song, JJ. et al., "The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes," Nature Struct. Biol., 2003, 10(12), 1026-1032	
753	Soutschek, J. et al., "Therapeutic silencing of a endogenous gene by systemic administration of modified siRNAs," Nature, 2004, 432(7014), 173-178	
754	Sproat, et al., "Highly Efficient Chemical Synthesis of 2"-O-methylioligoribunocleotides and Tetrabiotinylated Derivatives; Novel Probes That are Resistant to Degradation by RNA or DNA Specific Nucleases", Nucleic Acids Research, 1989, 17, 3373-3386	
755	Sproat, et al., "New synthetic routes to protected purine 2'-O-methylriboside-3'-O-phosphoramidites using a novel alkylation procedure", Nucleic Acids Research, 1990, 18, 41-49	
756	Steffens, R., et al., "168. Nucleic-acid analogs with constraint conformational flexibility in the sugar-phosphate backbone "tricycle-DNA'," Helv. Chim. Acta, 1997, 80, 2426-2439	
757	Stein, et al., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review", Cancer Research, 1988, 48, 2659-2668	
758	Stein, et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research, 1988, 16, 3209-3221	
759	Struck, "Vaccine R&D Success Rates and Development Times," Nature Biotechnology, May 1996, 14, 591-593	
760	Stufkens, et al., "Dynamic Jahn-Teller Effect in the Excited States of SeCl62-, SeBr62-, TeCl62- and TeBr62-", Recueil des Travaux Chimiques des Pays-Bas 1970, 89, 1185-1201	
761	Suciu et al., "Synthesis of 9-(2,5-dideoxy-β-D-glycero-pent-4-enofuranosyl)adenine", Carbohydrate Research, 1975, 44, 112-115	
762	Sutcliffe, J.G. et al., "TOGA: An automated parsing technology for analyzing expression of nearly all genes," PNAS, 2000, 97(5), 1976-1981	

Substitute for 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Filing Date
First Named
Art Unit

Compl	ete if Known
Application Number	10/701,265
Filing Date	11-04-2003
First Named Inventor	Brenda F. Baker
Art Unit	1635
Examiner Name	Jennifer S. Pitrak
Attorney Docket Number	ISIS-5300

	NON PATENT LITERATURE DOCUMENTS		
763	Svinarchuk, F.P. et al., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups," Biochimie, 1993, 75, 49-54		
764	Tamanini, F. et al., "The fragile X-related proteins FXRIP and FXRZP contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins," Hum. Mol. Genet. (2000) 9(10):1487-1493		
765	Tang, XQ. et al., "2'-C-Branched Ribonucleosides: Synthesis of the Phosphoramidite Derivatives of 2'-C-Beta-Methylcytidine and Their Incorporation into Oligonucleotides," J. Org. Chem., 1999, 64(3), 747-754		
766	Tazawa et al., "A Novel Procedure for the Synthesis of 2'-O-Alkyl Nucleotides" Biochem., 1972, 11(26), 4931		
767	Thompson," Applications of Antisense and siRNAs During Preclinical Drug Development," DDT (2002) 7(17): 912-917		
768	Tidd, D.M. et al., "Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues," Anti-Cancer Drug Design, 1988, 3(2), 117-127		
769	To, KY. "Identification of differential gene expression by high throughput analysis," Comb. Chem. & High Throughput Screen, 2000, 3, 235-241		
770	U.S. Patent Application Serial No. 09/315,298 filed May 20, 1999, by Teng et al.		
771	U.S. Patent Application Serial No. 60/423,760 filed November 5, 2002, by Baker et al.		
772	Van der Krol, et al., "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences", BioTechniques, 1988, 6, 958-976		
773	Vickers, T.A. et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and Rnase H-dependent Antisense Agents," J. Biol. Chem., 2003, 278(9), 7108-7118		
774	Wada, A. et al., "Nuclear export of actin: a novel mechanism regulating the subcellular localization of a major cytoskeletal protein," EMBO J. (1998) 17:1635-1641		
775	Wahlestedt, C., et al., "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids," Proc. Natl. Acad. Sci. U.S.A., 2000, 97(10), 5633-5638		
776	Walder, et al., "Antisense DNA and RNA: Progress and Prospects", Genes & Development, 1988, 2, 502-504		
777	Walder, et al., "Role of RNase H in Hybrid-Arrested Translation by Antisense Oligonucleotides", Proc. Natl. Acad. Sci. USA 1988, 85, 5011-5015		

		Complete if Known			
Substitute for	Substitute for 1449/PTO		Application Number	10/701,265	
INFORMATION DISCLOSURE				Filing Date	11-04-2003
STATEMENT BY APPLICANT		First Named Inventor	Brenda F. Baker		
				Art Unit	1635
(use as many sheets as necessary)				Examiner Name	Jennifer S. Pitrak
Sheet	43	of	44	Attorney Docket Number	ISIS-5300
		•		•	•

	NON PATENT LITERATURE DOCUMENTS	
778	Wang, J., et al., "Syhthesis and binding property of an oligonucleotide containing tetrafluorophenoxazine," Tetrahedron Lett., 1998, 39, 8385-8388	
779	Wang, X. et al., "Modular Recognition of RNA by a Human Pumilio-Homology Domain," Cell (2002) 110:501-512.	
780	Wei, Z. et al., "Hybridization properties of oligodeoxynucleotide pairs bridged by polyarginine peptides," Nucleic Acids Res. (1996) 24(4):655-661.	
781	Wein, G. et al., "The 3'-UTR of the mRNA coding for the major protein kinase C substrate MARCKS contains a novel CU-rich element interacting with MRNA stabilizing factors HuD and HuR," Eur. 1. Biochem. (2003) 270:350-365.	
782	Wengel, J., et al., "LNA (locked nucleic acid)," Nucleosides, Nucleotides, 1999, 18(6 & 7), 1365-1370	
783	Wianny et al., "Specific interference with gene function by double-stranded RNA in early mouse development," Nature Cell Biology (2000) 2: 70-75	
784	Wilds, C.J., et al., "Duplex recognition by oligonucleotides containing 2-deoxy-2-fluoro-D- arabinose and 2'-deoxy-2'-fluoro-D-ribose. Intermolecular 2'-OH-phosphate contacts versus sugar puckering in the stabilization of triple-helical complexes," Bioconjugate Chem., 1999, 10, 299-305	
785	Williams, D.M., et al., 'Properties of 2'-Fluorothymidine-Containing Oligonucleotides: Interaction with Restriction Endonuclease EcoRV," Biochemistry, 1991, 30, 4001-4009	
786	Wolfe, S., et al., "The guache effect. Some stereochemical consequences of adjacent electron pairs and polar bonds," Acc. Of Chem. Res., 1972, 5, 102-111	
787	Wouters, J. et al., "5-Substituted Pyrimidine 1,5-Anhydronhexitols: Conformational Analysis and Interaction with Viral Thymidine Kinase," Bioorg. Med. Chem. Lett., 1999, 9, 1563-1566	
788	Wright, P. et al., "Large Scale Synthesis of Oligonucleotides via Phosphoramidite Nucleosides and a High-loaded Polystyrene Support," Tetrahedron Lett., 1993, 34(21), 3373-3376	
789	Wu, H. et al., "Properties of Cloned and Expressed Human RNase H1," Journal of Biological Chemistry 1999, vol. 274, pages 28270-28278	
790	Wu, X., et al., "Base-pairing systems related to TNA: α-threofuranosyl oligonucleotides containing phosphoramidate linkages," Organic Lett., 2002, 4(8), 1279-1282	
791	Yang, Y. et al., "HIV-1 TAT-mediated protein transduction and subcellular localization using novel expression vectors," FEBS Letters (2002) 532, 36-44.	
792	Yeung, et al., "Photoreactives and Thermal Properties of Psoralen Cross-Links", Biochemistry 1988, 27, 3204-3210	

Substitute for 1449/PTO
INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

Application Number 10/701,265 Filing Date 11-04-2003 First Named Inventor Brenda F. Baker Art Unit 1635 **Examiner Name** Jennifer S. Pitrak (use as many sheets as necessary) 44 Attorney Docket Number ISIS-5300 44

Complete if Known

	NON PATENT LITERATURE DOCUMENTS	_
793	Zamecnik, P.C. et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," Proc. Natl. Acad. Sci. USA, 1978, 75(1), 280-284	
794	Zamore, P.D. et al., "Ancient Pathways Programmed by Small RNAs," Science, 2002, 296, 1265-1269	
795	Zamore, P.D. et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell, 2000, 101, 25-33	
796	Zanta, M. A. et al., "Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus," Proc. Natl. Acad. Sci. USA (1999) 96:91-96.	
797	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," Cell, 2004, 118, 57-68	
798	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology," Current Pharmaceutical Biotechnology, 2004, 5, 1-7	
799	Zhang, H. et al., "Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fuminant hepatitis," Nature Biotech., 2000, 18, 862-867	
800	Zhang, J., et al., "PowerBLAST: A new network BLAST application for interactive or automated sequence analysis and annotation," Genome Res., 1997, 7, 649-656	
801	Zhang, Z. et al., "Uptake of N-(4'-pyridoxyl)amines and release of amines by renal cells: A model for transporter-enhanced delivery of bioactive compounds," Proc. Natl. Acad. Sci. USA (1991) 88:10407-10410.	
802	Zhao, Q. et al., "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," Biochemical Pharmacology, 1996, 51, 173-182	
803	Zhu, T. et al., "Oligonucleotide-Poly-L-omithine Conjugates: Binding to Complementary DNA and RNA." Antisense Res. Dm. 119931 3:265-275.	
804	Zon, "Oligonucleotide Analogues as Potential Chemotherapy Agents", Pharm. Res., 1988, 5(9), 539-549	
805	Zon, "Synthesis of Backbone-Modified DNA Analogues for Biological Applications", J. Protein Chemistry, 1987, 6, 131-145	
806	Zuckermann, R. N. et al., "Site-Selective Cleavage of RNA by a Hybrid Enzyme," J. Am. Chem. SOC. (1988) 110:1614-1615.	